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Abstract
Stem cells can be efficiently differentiated into cardiomyocytes for use in disease
modeling and therapeutics. However, their development does not progress beyond the
late embryonic stage when cultured in the dish. To identify regulators of maturation,
we used large-particle sorting and single cell RNA-seq to analyze cardiomyocytes from
neonatal to adult mice. Analysis predicted PGC1α as a top target. A conditional
mosaic knockout was used to determine the cell autonomous effect of PGC1. PGC1 is
both required for cardiomyocyte maturation and is able to promote stem cell-derived
cardiomyocyte maturation in vitro. An siRNA screen found that YAP1 and SF3B2
mediate the effects on maturation through regulating hypertrophic growth and calcium
handling. This work provides insights into the complex gene regulatory network behind
cardiomyocyte maturation.
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Heart disease is the leading cause of death worldwide.1 Heart failure can result from
a slide in global heart function following myocardial infarction. Up to 25% of heart
muscle can be lost in an ischemic event.2 While diet and exercise changes along with
cholesterol-reducing statins can lower the risk of an arterial blockage, the heart is not
a regenerative organ.3 Over the course of 6 weeks, the infarcted region will have an
inflammatory response that activates myofibroblasts to secrete collagen and form scar
tissue.4 This heart remodeling can lead to thinning of the wall and dilation of the
heart in an effort to maintain blood flow to other organs.4 There is a clinical need
for replacing the lost beating heart muscle. One method of cardiac regeneration is
to grow cardiomyocytes in vitro then graft them into the heart as single cells or an
engineered heart tissue patch.5 However, pluripotent stem cell-derived cardiomyocytes
(PSC-CMs) are immature leading to arrhythmias.6
Another application of PSC-CMs is in drug discovery and pharmacological testing.
Drugs in development are flagged for possible off target effects on cardiomyocytes.7
However, the primary test for this is in animal models, which differ from human CMs.
For example, the mouse has a resting heart rate 10x that of humans and lacks key
ion channels.8 In addition, the predominant isoform for key contractile proteins is
1
different. In the past, drugs have been falsely rejected that have no effect on the
human heart and drugs have passed screening that did have effects on heart function.4
Therefore, there is a need for a screening method that accurately predicts how a drug
will affect human cardiomyocytes.9 Organoids and engineered heart tissues provide a
platform for testing, but immature PSC-CMs may create false positives. Maturation
is an obstacle limiting the translational potential of PSC-CMs.
Stem cell-derived cardiomyocytes
Pluripotent stem cells have been derived from embryonic origin. More recently, it
was found that somatic cells, such as dermal fibroblasts, can be reprogrammed into
pluripotent stem cells (iPSC).10 Both types are able to differentiate into endodermal,
mesodermal, and ectodermal lineages.11 Cardiomyocytes were initially found to be
present in embryonic cell aggregates called embryoid bodies at very low levels.2
PSCs can be efficiently differentiated by sequentially treating PSCs with recombinant
protein cytokines that were found during heart development.2 Further, small molecule
differentiations have been found to yield 90%+ differentiations by activating and
inhibiting the Wnt pathway.3
Development and Maturation
Embryonic heart development
In development, the heart is the first organ to form and grows from two populations,
the first and second heart field.10 These mesodermal progenitors begin looping and
form four separate chambers at E8.5 and E14.5, respectively. The CMs have already
committed to their cell fate by E10.5, but they are unlike their neonatal and adult
selves. Maturation is the individual cell transformation where cardiomyocytes undergo
morphological, functional and transcriptomic changes.12 Here, I will describe the
2
various hallmarks of maturation.
Morphology
PSC-CMs are visibly different from adult CMs. As CMs mature, they increase in
volume 30-40 fold, elongate into a rectangular structure.13,14 The sarcomeres are
parallel to each other and align with the long axis of the CM. Transverse-tubules form
as invaginations of the plasma membrane to allow the action potential to synchronous
calcium release and contraction in the cell.15,16 PSC-CMs on the other hand are highly
variable in shape as they are more circular with misaligned sarcomeres and do not
have T-tubules.17 Part of this may be due to in vitro culture of PSC-CMs on a flat
rigid surface.18,19
Intercalated discs
In vivo CMs form connections with neighboring CMs to improve force and action
potential conduction.20 The CMs are electrically coupled through gap junctions made
from Connexin 43, which allows ions to travel between cells.21 The intercalated discs
also have desmosomes to link intermediate fibers with other cells and fascia adherens
to connect sarcomeres. In PSC-CMs, Connexin 43 is distributed around the cell
membrane rather than in punctate dots at the ends of adult CMs.22 This leads to a
lack of anisotropy in conduction velocity.23
Electrophysiology
PSC-CMs spontaneously contract, while adult CMs do not usually contract without
stimulation. The beating rate is generally 40 beats per minute and is attributed to
expression of the funny channel HCN4 which leaks sodium current.24 This may also
be caused by spontaneous calcium release that results in depolarization as sodium
flows in through the calcium-sodium exchanger. The resting membrane potential
3
in PSC-CMs is often between -50 to -60 mV, which is higher than mature CMs at
-90 mV.14 All of these combine to form an abnormal action potential shape when
compared to adult CMs. The action potential shape can be quantified by a number of
parameters including dV/dtmax, which is a measure of sodium influx speed and is
lower in PSC-CM, and a shorter action potential duration (APD50) indicative of a
shorter plateau phase. These changes may be due in part to downregulation of major
ion channel expression including the inward rectifying potassium channels KCNH2
and KCNJ12.6 Differences in upstroke velocity may be caused by lower levels of the
voltage-gated sodium channels SCN5A.22 Patch clamping of PSC-CMs shows barely
detectable levels of the slow delayed-rectifier potassium current, contributing to the
lack of a plateau phase in the action potential.
Calcium Handling
Calcium plays a central role in excitation contraction coupling. Excitation-contraction
coupling is the process linking a depolarization from an action potential to sarcomeric
shortening through opening of voltage-sensitive L-type calcium channels, located in the
t-tubules, to allow calcium to flow into the cell.25 This calcium influx leads to a calcium
induced calcium release of the calcium in the sarcoplasmic reticulum through ryanodine
receptors. The cytosolic calcium then binds troponin-C, a subunit of troponin, that
leads to a conformational change in troponin moving the tropomyosin and allowing the
myosin head to bind the actin pulling the sarcomere z-bands together.22 The calcium
is then pumped into the sarcoplasmic reticulum through SERCA2A and out of the
cell allowing relaxation of the sarcomere. The intracellular calcium concentration can
be measured by fluorescent video imaging of a calcium-sensitive dye to construct a
trace of the calcium transient. PSC-CMs have both slower release and reuptake of
calcium. In addition, PSC-CMs are often insensitive to drugs that alter SR release and
uptake. This may be caused by dysregulation of calcium handling gene transcription
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as calsequestrin and phospholamban are present at low levels.26
Contractility
Adult human cardiac myocytes produce 44 mN/mm2 peak twitch force.6 PSC-CMs
contract with less than 1% of this force. Neonatal rat ventricular myocytes produce
similar amounts of force. Engineered heart tissues (EHTs) have been shown to generate
nearly 13 mN/mm2 of this after long term culture with mechanical and electrical
stimulation.27 The length of a relaxed, adult sarcomere is 2.2µm while PSC-CM
sarcomeres are 1.7 µm.28 The contractile immaturity may be based on the expression
of immature isoforms of titin, myosin light chain 2, myosin heavy chain, and troponin
I. PSC-CMs also express non-myocyte genes including smooth muscle α-actin and
vimentin.
Proliferation and multinucleation
Embryonic CMs divide as heart growth is driven by proliferation. In the perinatal
window, they withdraw from the cell cycle and transition into hypertrophic growth.
During this time, the majority of cells transition from mononucleated to multinucleated
through DNA synthesis and nuclear division without cytokinesis.29 Most human CM
nuclei will become polyploid. Not much is known about what drives polyploidization,
but it is possible that this and the loss of regenerative capacity may be related to
thyroid hormone concentration.30 Binucleation rate differs by species as 3 in 4 CMs are
binucleated in rodents while only 1 in 4 CMs are binucleated in humans.2 The heart
is one of the least regenerative organs as CM proliferation in healthy and diseased
hearts is very low. Maturation has been studied in multiple animals including sheep
and swine. While the rates of development and maturation differ, the hallmarks are
the same.31
Activating CM proliferation to induce cardiac regeneration could be a treatment
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for ischemic heart disease. The proportion of mononuclear CMs is linked with the
regenerative potential and is dependent on the background genetics, which varies
greatly in different mouse strains.32 Cell cycle withdrawal has been found to be
regulated by many genes and pathways including microRNAs, hippo/YAP, ERBB2,
PI3/Akt, cyclins, cyclin-dependent kinases, and inhibitors of cyclin dependent kinases.
Metabolism has been linked to proliferation as changes in glucose and fatty acid
concentrations in media alter Ki67+ cells. Oxidative DNA damage may drive cell
cycle exit in CMs as this coincides neonatally with increased oxygen levels. Exposing
mice to hypoxic conditions has been shown to produce a regenerative response.33
Overexpression of cell cycle regulators CDK1, CDK4, cyclin B1, and cyclin D1 in the
mouse heart induced CM division.34 PSC-CMs divide frequently during differentiation
and are able to divide long after differentiation if cultured in vitro, but the rate of
proliferation decreases from 30% to less than 5% of cells. PSC-CMs can continue to
proliferate if they are cultured at low densities with Wnt modulation.35
Metabolic maturation
Immature CMs primarily use glucose as their source of energy, but transition to fatty
acid postnatally due to an increase in energy demand and oxygen levels.36 Glycolysis
produces 2 ATP molecules per glucose, while fatty acid β-oxidation of palmitate
can generate 129 ATP molecules.37 The majority of the ATP is used for contractile
function with the next largest sink being SERCA and other ion pumps. Mitochondrial
density expands rapidly and they change morphology by becoming oval shaped and
increasing in size.38 The mitochondrial permeability transition pore is open in fetal
myocytes. While an open state in adults drives apoptosis by leaking cytochrome c
in adult mitochondria, it lowers the mitochondrial membrane potential in fetal CMs
and lowers their ability to perform oxidative phosphorylation.39 In addition, cristae
become very dense in adult CMs compared to the low density of cristae. This density
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is directly related to the capacity for respiration. PSC-CMs resemble fetal myocytes
in their reliance on glycolysis and mitochondrial ultrastructure.38
Methods of improving maturation
Microenvironment
Many microenvironmental strategies have been applied to PSC-CMs to improve
maturation. One has been to culture PSC-CMs on a deformable surface. This allows
the culture surface to match the stiffness of the in vivo heart (10 kPa) as rigid cell
culture plastic is very stiff (1 MPa).29 Polyacrylamide, PDMS, or hydrogels that
can be tuned to a specific Young’s Modulus. This allows PSC-CMs to become more
rectangular and mature.40 A theme of many of these approaches is to create biomimetic
solutions to recreate an in vivo environment. Specific extracellular matrix (ECM)
molecules are also regulators of maturation as Laminin-511/521 potently enhances CM
maturation aspects including increased maximal respiration and binucleated cells.41
Electrical and mechanical stimulation stimulation
In the heart wall, CMs are electrically stimulated and subjected to stretching. Culture
systems have been set up to mimic these conditions in vitro. A 3D self organized
tissue ring was designed to allow the action potential to propagate around the ring
repeatedly with the goal of maturing myocytes.42 Others have used a micropillar
electrode array to mature cardiac spheroids.43 it has been shown that introducing
electrical stimulation during differentiation can increase the proportion of conduction
system cells.44 Electrically conductive extracellular materials added to engineered
heart tissue patches improve maturation with better alignment of sarcomeres and the
formation of an initial intercalated disc.45
Mechanical stimuli is translated to changes in cell morphology and gene expression
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through mechanotransduction. Cyclic stretching leads to elongation and more CMs
with a rod-like shape.25 Mechanical stress results in improved contractile properties
and an increase in expression of β-myosin heavy chain and cardiac troponin T.12 It
has been proposed that hypoplastic right ventricle congenital heart disease is due to a
defect in maturation during development.46
Hormone treatment and biochemical cues
Treatment with hormones has been shown to improve maturation. Specifically tri-
iodothyronine (T3), which binds the thyroid hormone receptor, and dexamethasone,
which binds the glucocorticoid receptor, promote morphological maturation in addition
to functional aspects. Using a combination of these, a team was able to see t-tubule
formation in PSC-CMs when also cultured on a matrigel mattress.47 One-week of treat-
ment with T3 was able to increase CM size, sarcomere length, cyclin-dependent kinase
inhibitor p21 expression, contractile force, and mitochondrial respiratory capacity.48
Knockout of the thyroid hormone receptor leads to immature myocytes that are
proliferative in response to injury.30 Recent efforts have confirmed the role of dexam-
ethasone in maturation and found that it acts by promoting mitophagy leading to
lysosomal aggregation in mitochondria. By blocking mitophagy, they were able to
negate the effects of dexamethasone on CM maturation.49 Retinoic acid has also been
found to promote maturation, specifically increasing mitochondrial DNA copy number,
electrophysiological parameters, oxidative phosphorylation, and calcium handling.50
Retinoic acid binds to the retinoic acid receptor (RAR) which heterodimerizes with
PPAR family members. Pharmacological inhibition of centrosomes was able to prevent
cell division pushing PSC-CMs towards a matured state.51 Other soluble factors may
promote CM as blocking excretion of these from the placenta resulted in less mature




Others have looked into the co-culture of PSC-CMs with fibroblasts, endothelial cells
(ECs), smooth muscle cells, or neurons since these cell types are present in the heart.
CMs make up 80% of the volume, but roughly 30% of the cells by number.53 The
non-myocytes can secrete growth factors like VEGF and bFGF, which improve differ-
entiation and function. They can also alter the ECM to deliver microenvironmental
cues to CMs.23 3D culture systems often put together a combination of these factors
by creating an engineered heart tissue between two deformable posts. Fibroblasts are
added to provide structure and the systems allow for electrical pacing. Single cell
RNA-seq analysis of fibroblasts in the developing mouse heart showed they have stage
specific subtypes and influence CM maturation by modulating the microenvironment.54
Giacomelli and colleagues constructed 3D microtissues using CMs, fibroblasts
and ECs. They found that PSC-CMs formed t-tubules, with improved contractility,
respiration, and action potential parameters.55 They proposed that this occurs through
the coupling by Connexin 43 gap junctions and higher intracellular cyclic AMP levels.
Co-culture with sympathetic neurons results in improved maturation of both cell types.
The neurons are able to couple and modulate the beating rate as they do in vivo.
The sympathetic neurons were differentiated from PSCs and could be optogenetically
excited.56
Altering metabolism
Many of these pathways have been shown to be interconnected and tied to metabolic
maturation.57 Most culture media contains a high concentration of glucose. How-
ever, recent studies have shown that low glucose, fatty acid-rich media promotes
maturation.58 This is seen in vivo as postnatal CMs switch from glycolysis to fatty
acid oxidation as their primary source of energy. These studies added oleic acid,
carnitine, linoleic acid, and palmitate and saw a switch of energy source, mitochondrial
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number, and structural maturation.59,60 Conversely, the high levels of glucose in normal
media was shown to inhibit CM maturation.39 In vivo, the reduction in glucose uptake
begins in late gestation and it was found that glucose promotes nucleotide biosynthesis
via the pentose phosphate pathway.61 The mitochondrial permeability transition pore
can be closed using cyclosporine A to induce mitochondrial maturation.62 PSC-CMs
matured with a medium containing oxidative substrates was able to improve PSC-CM
function in modeling long QT syndrome and dilated cardiomyopathy.63
In vivo transplantation
The only method that has yielded mature myocytes has been the in vivo transplantation.64
Our group has shown that mouse PSC-CMs injected into the neonatal rat heart leads
to mature myocytes 1-2 months later. However, if they are injected in the adult
or later postnatal hearts, they do not fully mature. This could indicate that there
is a critical window where microenvironmental or biochemical cues instruct CMs
to mature. This was not confirmed by the other study of in vivo transplantation
that saw mature myocytes form in adult hearts.65 However, that study focused on
morphological and immunostaining of myofilament proteins that switch isoforms rather
than functional endpoints. Initial studies indicate that species matching is required
as human PSC-CMs injected into the macaque heart matured, but human PSC-CMs
injected into rat hearts remained immature. One drawback from this is that it is
extremely low throughput yielding hundreds of mature CMs. This is due to the size
of the rat heart and low engraftment of injected PSC-CMs. The largest conclusion
is that it is possible for PSC-CMs to become fully mature. Injecting PSC-CMs into
adult athymic rats and subsequent single cell RNA-sequencing showed upregulation of
mature gene markers and pushed the cells toward ventricular phenotypes.66
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Combination approaches
Since multiple biochemical factors have been shown to promote maturation, it was
found that a combination of T3, dexamethasone and insulin-like growth factor-1
improved multiple aspects of maturation although not synergistically.67 A similar
study combined microgroove alignment with T3 and electrical pacing finding that some
microenvironmental stimuli can prime CMs for other biochemical cues to enhance
maturation.68 One study seeded single PSC-CMs into a rectangular scaffold and results
indicated that transcriptomic and functional calcium handling changes occurred.69
Exposing PSC-CMs to pulsatile hemodynamic forces improves by maintaining oxygen
levels and mimicking blood flow.70
PSC-CMs can be aggregated into engineered heart tissue (EHTs) and organoids to
better model the myocardium. In a combination of electrical and mechanical stimuli
from C-Pace IP from Ionoptix and a custom PDMS channel to create cyclic stretch,
LaBarge et al. found that PSC-CM spheroid maturation was promoted after 7 days
of stimulation compared to unstimulated spheroids.71 Using cardiac organoids made
from PSC-CMs in a 96-well format, Mills and colleagues screened growth factors,
metabolic substrates, and ECM to optimize CM maturation.72 While all of these have
improved maturation, none have produced adult-like myocytes that can match the
force production and lack of spontaneous beating.
Transcriptomic maturation
CM maturation encompasses differential expression of thousands of genes. There
are multiple isoforms of contractile proteins with each being associated with skeletal
or cardiac muscle and fetal or adult stages. Troponin I is a contraction regulatory
protein that is responsible for sensing calcium and allowing myosin to bind actin
in the excitation-contraction coupling. Embryonic cardiomyocytes express the slow
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skeletal muscle isoform in the TNNI1 gene, but switch to expression of the cardiac
isoform TNNI3 after birth.25 This change is conserved in rodent and human hearts.
This isoform switch has functional consequences as TNNI3 leads to increased tension
and has different calcium affinity. Myosin heavy chain, a motor protein, also has an
isoform switch. In humans, the alpha isoform MYH6 is expressed fetally and the beta
isoform MYH7 is expressed in adults. However, this switch is the opposite in rodents
as they express MYH6 in the adult heart which leads to faster activity and binding
which is required as their heart rate can reach 800 beats per minute. In addition to
temporal specific switches, there are spatial changes as myosin regulatory light chain 2
(MLC2 ) has isoforms associated with atrial and ventricular CMs. These myofilament
protein expression changes and are partially captured in PSC-CM long term culture.
Forced expression of the adult form of cardiac troponin I in PSC-CMs was able to
promote CM maturation by altering relaxation kinetics.73 While the cellular identity
of cardiomyocytes does not change, there is a shift in the transcriptomic signature.
Gene regulatory network of maturation
The use of high throughput sequencing has begun to characterize the gene regulatory
network (GRN) of maturing myocytes. This has been focused on identifying critical
proteins required for CM maturation through knockout screens. A landmark study
in the field used a meta-analysis of more than 200 microarray datasets to build
a study of mouse heart development and maturation from early embryonic stages
to adult hearts. This identified predicted upstream regulators and the temporal
dynamics of key pathways.74 Mechanical forces are known to regulate CM maturation
so Fukuda et al. looked into the mechanism of how cells translate mechanical stimuli
into transcriptional changes. They found that vinculin is essential for maturation and
recruits slingshot protein phosphatase SSH1 and actin depolymerizing factor cofilin
to regulate myofilament maturation.75,76 mTOR-signaling pathway has been shown
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to promote maturation by increasing expression of p53 to push CMs into a quiescent
state.77 Treated PSC-CMs showed better contractility with improved mitochondrial
capacity.
Multiple factors have now been implicated in the regulation of CM maturation. The
Estrogen-Related Receptor (ERR) has been identified as a nuclear receptor required
for maturation.78 Knocking out ERR in vivo was perinatally lethal with CMs showing
arrested maturation. ERR was found to regulate key maturation genes by suppressing
those associated with fibroblasts and directly activating cardiac contractile machinery
genes. The maturation of the mitochondria, corresponding to an increase in size and
cristae density, was found to be regulated by BUD23-dependent ribosome generation.79
Knocking out BUD23 led to cardiomyopathy and death due to lower mitochondrial
function. In a study of regeneration, it was found that Meis1 is a cofactor of Hoxb13.
They are regulated by calcineurin, a calcium-activated phosphatase, and control genes
involved in CM maturation, hypertrophy, and cell cycle progression.80
In vivo postnatal maturation was elegantly probed through the use of the CRISPR/Cas9-
AAV based somatic mutagenesis (CASAAV) system to generate a mosaic knockout in a
fraction of the cells to prevent effects on CMs associated with global heart dysfunction.
CASAAV uses an AAV9 vector to introduce guideRNAs targeting the gene of interest
for loss of function into a Cre-inducible Cas9-GFP for somatic mutagenesis.81 Serum
response factor (SRF), which had previously been shown to be required for maturation
using a conditional knockout, was found to regulate T-tubule formation, cell size, and
sarcomere ultrastructure.82 Interestingly, knockout of SRF in the adult heart did not
result in the same changes suggesting SRF is required for a stage specific maturation,
but not maintenance of adult function. This study did not investigate whether SRF
activation promoted maturation of PSC-CMs. This technique was also applied to
build an in vivo CRISPR genetic screen in the mouse heart. A library of guideRNAs
was to create a high throughput, low animal method for assessing the relevance of
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genes to CM maturation. Among the top hits were RNF20 and RNF40. They found
that these were epigenetic transcriptional regulators of key genes for CM maturation.
Single cell RNA sequencing of cardiomyocyte mat-
uration
Time series analysis of single cell RNA-seq have provided insights into changes during
maturation. This has been applied to PSC-CM differentiation where one study found
HOPX to be a regulator of hypertrophy and is expressed in long term PSC-CM culture.
They overexpressed HOPX in PSC-CMs and found that it increases cell size. While
they identified a key regulator of PSC-CM maturation, it may be more important to
study in vivo myocytes that actually become fully mature.83 One of the first datasets
generated of CM maturation was Delaughter et al.’s study of heart development.
They used drop-seq on more than 1,200 cells from E9.5 to P21. However, the quality
of reads and CM number after P3 sharply dropped off due to CM shearing in the
microfluidics channels used to encapsulate cells in drop-seq.84 Their study groups
cells by spatiotemporal location and were able to use principal component loading to
determine the maturation of PSC-CMs, which they showed were closest to E14.5 at
30 days of culture and E18.5 at one year of culture. Due to the limitations of sorting
CMs, single nucleus RNA-seq has been used to study maturation. However, this lacks
read depth and mitochondrial reads important to aspects of GRN reconstruction and
cell signature determination.
Other methods have been developed to quantify the maturation state of PSC-CMs.
Entropy, a measure of the distribution of reads among genes, can determine the
maturation status as adult cells have reads more concentrated in a smaller number of
highly expressed genes. Individual maturation markers including Myom2 have been
found that correlate highly with maturation and increase 8 fold from embryonic to adult
stages.74 Proteomics has been used to quantify the protein levels of specific maturation
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markers such as MYOM1 and TMEM65.85 Cell surface markers of maturation are
particularly useful for sorting PSC-CMs using FACS. CD36, a fatty acid translocase,
was identified as a marker of maturation that striated CMs by maturation status.86




Identifying upstream regulators of
cardiomyocyte maturation
Background
Our strategy to improve PSC-CM maturation is to correct dysregulated gene expression
by studying the expression patterns in the mouse heart. The goal is to characterize
the gene regulatory network of CMs across multiple stages of development to see
where PSC-CMs differ. Our group had previously generated a large meta-analysis
data set that has been used to track gene expression from the early embryo to adult.74
The study concluded that PSC-CM maturation is arrested at the late embryonic
to early postnatal function. Therefore, we needed better temporal resolution and
improved sequencing depth as they had used microarray which provides less reliable
normalization. We intend to use gene regulatory network prediction algorithms to
identify potential drivers of maturation.
Cardiac cell atlases
Other groups have generated large datasets looking into the maturation of CMs.84,87,88
However, they usually focus on early development and formation of the heart or on
the adult stage. Another problem is that CMs were sorted using conventional FACS or
drop-seq, which is not suited to the large size of CMs. These datasets then have poor
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cell survival as the sorting and isolation process leads to apoptosis and cell shearing.84
We have recently shown that CMs can be successfully sorted and sequenced using
large particle FACS.89
In this chapter, we sought to identify upstream regulators of CM maturation. To
do this, I gathered public RNA-seq datasets spanning postnatal CM development.
We used bioinformatic analyses to predict based on gene expression changes. To
gain improved resolution, we used single cell RNA-seq to track the heterogeneous
maturation of the mouse heart.
Materials and Methods
Collection of raw data
Datasets were selected using Gene Expression Omnibus (GEO) for cardiomyocyte or
heart high throughput sequencing of timepoints in late embryonic, postnatal or adult
stages in mice. Mouse embryonic stem cell-derived cardiomyocyte datasets were also
collected. FASTQ or SRA files for each dataset were downloaded from the Sequence
Read Archive or European Nucleotide Archive.
Mapping and Alignment
FASTQ file quality scores were assessed using FastQC.90 Reads were trimmed using
trimmomatic sliding window quality cutoffs to remove nucleotides with quality cutoff
of 35. They were mapped to the mm10 genome using HISAT2.91 Mapped reads were
aligned to exons using RefGene using subRead featureCounts and output as a counts
table.92
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Differential expression, principal component, and pathway anal-
ysis
The counts table was imported into R for analysis using DESeq2.93 Following size
factor normalization, differential expression statistics were calculated. Principal
component analysis was performed using a wrapped prcomp function on the rlogged,
normalized counts. Ingenuity Pathway Analysis (IPA) was used to generate predicted
upstream regulators using gene regulatory networks.94 DAVID was used to assess
KEGG enrichment and PantherGO with Revigo TreeView was used to visualize gene
ontology terms.95,96 Mitochondrial gene expression was visualized in a heatmap from
with pheatmap.
Neonatal Cardiomyocyte isolation
For P0 cardiomyocyte isolation, the Miltenyi Biotec gentleMACS Dissociator was
used with the neonatal mouse heart dissociation Kit. P0 mouse hearts were harvested
and transferred into PBS on ice then pumped to wash out blood. Under a dissection
microscope, blood vessels and connective tissue were removed. Enzyme mix 1 was
incubated at 37 C for 5 minutes then 2362.5 µL were added to 127.5 µL of enzyme
mix 2. The ventricles were placed in a gentleMACS C Tube and the supernatant
was removed. 2.5 mL of the enzyme mix were added to the C Tube. The tube was
tightened and then inverted and placed cap down in an incubator at 37 C for 15
minutes. The C Tube was placed on the sleeve of the gentleMACS Dissociation and
the gentleMACS m_neoheart_01 program was run. The 15 minutes of incubation
and program were repeated twice more. Afterwards, the C tube was detached and
7.5 mL of DMEM+10% FBS was added. The solution was then filtered through
the pre-separation 70µmfilter and 3 mL of media were used to wash through any
additional cells. The flow through was then centrifuged at 300 rcf for 15 minutes. The
supernatant was aspirated then the cells were resuspended in the media.
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Adult Cardiomyocyte Isolation
Mouse hearts aged P7 to P56 were isolated in this manner. A non-hanging langendorff
perfusion was used to dissociate the hearts as previously described.64 First, the mouse
was anaesthetized with isofluorane. If they were unresponsive to a toe pinch, they were
euthanized by cervical dislocation. The mice were not heparinized so the heart excision
and cannulation was performed rapidly. The hearts were perfused with a digestion
buffer for 6-9 minutes depending on the age of the mouse at 1.5 mL per minute to
enzymatically degrade the extracellular matrix. The perfusion buffer contained 120
mM NaCl, 1 mM MgCl2, 5 mM 2,3-butanedione monoxime (a non-selective myosin
ATPase inhibitor), 5 mM Taurine, 5.5 mM glucose, 20 mM NaHCO3, 5.4 mM KCl,
and 1.2 mM NaH2PO4 which is then set to pH 7.4. The digestion buffer is 40 mL
of the perfusion buffer with 2 mg Protease (Sigma P5147) and 35.8 mg Collagenase
Type II (Worthington CLS-2). The ventricle was cut from the cannula and minced
for 30 seconds using scissors in 10 mL of perfusion buffer. The mixture was pipetted
vigorously up and down using a wide tipped plastic eye dropper to dissociate CMs. The
mixture was filtered through a 100µmscreen to remove large chunks then centrifuged
for 1 minute at 800 RPM in an Eppendorf 5702 centrifuge). It was resuspended in 10
mL of Tyrode’s buffer with bovine serum albumin to stop the enzymes. CMs pelleted
at the bottom by gravity over 10 minutes. The supernatant was removed and cells
were resuspended in 10 mL of Tyrode’s buffer in a small beaker.
Gene regulatory network analysis
Weighted gene co-expression network analysis was used to identify modules of co-
expressed genes in CM maturation.97
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Statistics
IPA generates a z-score for confidence of upstream regulator activation and a p-value
for each factor. KEGG generated a q-value of for the enrichment of each term. Top
terms were shown and ranked by q-value in figure 2-2.
Single cell sequencing
mcSCRB-seq was used to prepare libraries.98 Cells were sorted directly into a 96 well
U-bottom plate using the Union Biometrica COPAS-FP-500 LP-FACS. Each well
contained 4 µL lysis buffer made of 411.4 µL ultrapure RNase-free water, 27.5 µL of 20
mg/mL Proteinase K, and 1.1 µL of 5x NEB HF Phusion buffer. Each well contained
1 µL of barcoded oligo-dT primer at 2 uM. Following sorting, they were sealed and
placed directly on dry ice then stored at -80 C until library preparation. Plates were
thawed at room temperature then spun down for 30 second at 1000 rcf. They were
then placed in a thermocycler for 10 minutes at 50 C for Proteinase K digestion, then
80 C for 10 minutes for heat inactivation. Reverse transcription mix was prepared by
adding 88 µL of ultrapure water, 165 µL PEG 8000, 220 µL 5x Maxima RT buffer, µL
of 25 mM dNTPs, 22 µL TSO E5V6NEXT unblocked 100 uM, and 11 µL Maxima H
Minus RT (200 units/uL). 5 µL was added to each well then sealed and centrifuged
at 1000 rcf for 30 seconds. The 96 well plate was incubated in a thermocycler for 90
minutes at 42 C. Next, pooling beads were prepared by adding 15 g PEG 8000, 20 mL
of 5M NaCl, 500 µL 1M ph 8.0 Tris-HCl, 100 µL 0.5 M EDTA, 50 µL IGEPAL 10%
solution, 250 µL Sodium Azide 10% solution, and ultrapure water to bring solution
to 50 mL. PEG was solubilized in solution by incubating at 40 C and vortexing.
Sera-Mag Speed Beads were resuspended in the bead stock. All wells were pooled in
a 2 mL tube then 960 µL of the Pooling Beads were added and incubated at room
temperature for 5 minutes to allow cDNA binding to beads. Beads were magnetically
pulled down and the supernatant was removed and discarded. They were washed
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with 1 mL of 80% ethanol twice then air dried for 5 minutes. cDNA was eluted by
adding 17 µL of ultrapure water. This was transferred to a new tub and added to
2 µL of exonuclease 10x buffer and 1 µL of exonuclease (20 units/uL). The library
was placed in a thermocycler for 20 minutes at 37 C for exonuclease digestion then
10 minutes at 80 C for heat inactivation. The pre-amplification mix was prepared
by combining 25 µL of 2x terra direct buffer, 1 µL of 10µmSINGV6 primer, 1 µL of
Terra polymerase (1.25 units/uL), and 3 µL of ultrapure water which was added to
the digested sample. The 50 µL sample was amplified in a thermocycler by 3 minutes
at 98 C then 15 cycles of 15 seconds at 98 C, 30 seconds at 65 C, then minutes at
68 C, followed by 10 minutes at 72 C. Clean up beads were washed with a solution
containing 11 g PEG 8000, 10 mL of 5M NaCl, 500 µL 1M ph 8.0 Tris-HCl, 100 µL
0.5 M EDTA, 50 µL IGEPAL 10% solution, 250 µL Sodium Azide 10% solution, and
ultrapure water to bring solution to 50 mL. The solution was added to the beads
then washed after adding additional Tris-HCl and EDTA. 40 µL of clean-up beads
were added to the PCR result and set at room temperature for 5 minutes. Beads
were pulled down on a magnetic stand and washed twice with 150 µL of 80% ethanol.
cDNA was eluted with 15 µL of ultrapure water then the concentration was quantified
using high sensitivity DNA Qubit. For tagmentation, 10 µL of tagment DNA buffer
(2x was added to 5 µL of Amplicon tagment mix, 4 µL of ultrapure water, and 1 µL
of diluted cDNA (0.8 ng/uL). This was then incubated at 55 C for 10 minutes in a
thermocycler. The reaction was stopped by adding 5 µL of NT buffer, pipetted upland
down then incubated at room temperature for 5 minutes. For 3’ enrichment PCR, 15
µL of NPM PCR Mix, 0.5 µL of P5NEXTPT5 (5 uM), and 9 µL ultrapure water were
added to the sample along with 0.5 µL i7 index primer. It was then cycled through
13 cycles of 10 seconds at 95 C for denaturation, 30 seconds at 55 C for annealing,
and 1 minute at 72 C for elongation which was preceded by 3 minutes at 72 C and
followed by 5 minutes at 72 C. The result was mixed with 50 µL clean-up beads for 5
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minutes at room temperature. It was pulled down with a magnet and washed twice
with 150 µL of 80% ethanol. cDNA was eluted with 20 µL of ultrapure water then
run for 10 minutes on a 2% Agarose E-Gel EX. The gel frame was pried open and
the library was excised by cutting from 300 to 900 bp with a scalpel. The Qiagen
MinElute Kit was used to isolate the cDNA from the agarose gel. Briefly, 450 µL
of Buffer QG was added to the gel in a 1.5 mL eppendorf tube and incubated at 42
C for 10 minutes. 150 µL of isopropanol was added to the sample and mixed, then
transferred to a spin column and centrifuged at 16,000 rcf for 1 minute. The flow
through was discarded and 700 µL of Buffer PE was added then centrifuged as done
previously. The column was transferred to a new 1.5 mL eppendorf tube and 20 µL
of ultrapure water was added to the column then centrifuged again. Samples were
submitted to the Deep Sequencing and Microarray Core for quality control using the
Aligent 2100 Bioanalyzer with a High Sensitivity DNA Analysis kit. Libraries were
then pooled and sequenced on an Illumina NextSeq 500. Samples were demultiplexed
using bcl2fastq and mapped using the zUMIs master script.99
This contains spike-ins and UMIs to allow accurate counts of strands. Paired end
reads were sequenced with the Illumina NextSeq500 through the Deep Sequencing
and Microarray Core. zUMIs was used to map and count reads through STAR and
subRead featureCounts.92,99,100 The Monocle2 R package was used to order cells in
pseudotime then create a trajectory.101
Results
Development of a maturation transcriptome map
We built a meta-analysis dataset of publically available RNA-seq of the mouse heart.
We were able to collect embryonic (E14.5), perinetal (P0, P1), neonatal (P4, P7),
adolescent (P14), and adult timepoints. Clustering using PCA leads to clear grouping
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by time point with a clear temporal trend. A time series trajectory forms as principal
component 1 has most of the variance and is able to order the samples (Figure 2.1).
At this point, we notice that there are a few large jumps, particularly from P7 to P14,
which we describe as the critical window for maturation.
Figure 2-1. Principal component analysis of bulk RNA-seq meta-analysis of ventricular
and isolated myocytes. PC1 captures 45% of the variance and shows a clear temporal
trajectory
Isolated cardiomyocyte samples, which have been estimated by the authors to
be more than 95% cardiomyocytes, and whole ventricle samples were used. While a
third of the heart by volume contains nonmyocytes, predominantly fibroblasts and
endothelial cells, isolated and ventricle samples cluster closely. Although this study
contains samples from multiple institutions across several continents, large batch
effects were not observed in the PCA cluster although individual gene reads despite
normalization showed trends. In addition, the PSC-CM cells did not cluster closely
with the late embryonic cells, which they resemble morphologically and functionally.
After building a meta-analysis dataset that captured temporal maturation, I wanted
to see show the CM transcriptome changed as it matured. We know that contractile
proteins increase in expression and isoform switches occur specifically in Myh6/7 and
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Figure 2-2. KEGG analysis of deferentially expressed genes with at least 2 fold change
comparing early and late timepoints
TNNI1/3. However, the temporal change in all mRNA at this resolution and read
depth has not been determined. Differential expression analysis was performed and
yield with >2-fold change in expression and p-value <0.05. A KEGG analysis of the
upregulated genes (Figure 2.2) shows that the pathways for oxidative phosphorylation,
cardiac muscle contraction and PPAR signaling were enriched. Multiple top terms
were related to neurodegenerative diseases, but these show up because they have been
mechanistically linked to mitochondrial dysfunction. This finding supports functional
changes noted in maturation as immature CMs use glycolysis as their energy source
and adult CMs use fatty acid oxidation.
Generation of a gene regulatory network of maturation
With the goal of understanding which gene programs are activated during maturation,
we used weighted gene co-expression network analysis (WGCNA) to identify co-
expressed clusters across maturation. A heatmap showing coexpression between genes
and their assigned modules (Figure 2.3) indicates that specific clusters form through
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Figure 2-3. Weighted gene co-expression network heatmap for cardiac gene regulatory
network. Genes were hierarchically clustered and assigned module color is presented.
development and turquoise is the largest.
To track module relevance to maturation, the correlation of each module with
developmental time was computed (Figure 2.4). Gene ontology was used to summarize
the genes in the two top clusters that are the most strongly associated with correlation
positively (red) and negatively (turquoise). The GO terms were sorted by log of fold
enrichment and presented showing the red module contained metabolic and oxidative
phosphorylation genes. The turquoise module is a suppressed group of genes that are
related to activation of the cell cycle and mitosis. Once we identified genes within
the top correlation network module, we wanted to select the activated as potential
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targets for modulation to promote PSC-CM maturation. We found that the red
module contained 35 putative transcription factors including RXRG and PPARA,
which form a nuclear receptor transcriptional complex together, along with E2F6,
which is involved in suppressing cell cycle progression.
Figure 2-4. A. Correlation of gene module expression with CM maturation. B. Gene
ontology top terms for red module which is positively correlated with maturation. Axis
represents log of fold enrichment. C. Gene ontology top terms for turquoise module with
is negatively correlated with maturation.
Prediction of upstream regulators of postnatal maturation
We next wanted to use the bulk RNA seq to predict top upstream regulators, primarily
transcription factors, whose activation of genes matched the differentially expressed
genes. IPA Generated a Z score for activation and the top genes with the log fold
change (Figure 2.5).94
This identified a list of potential drivers of maturation. Nuclear receptors, specifi-
cally the PPAR family, showed up repeatedly on the top predicted upstream regulators
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Figure 2-5. Prediction of upstream regulators using Ingenuity Pathway Analysis
that also increased in expression by at least 1.5 fold. From this, we concluded that
PPAR is activated during postnatal maturation.
Single cell transcriptomics defines a maturation trajectory and
maturation scores
We designed a comprehensive analysis of cardiomyocyte maturation at postnatal stages.
We used myocytes collected at P0, P7, P14, P21, and P28. Previous studies have not
been able to generate high quality sequencing data because, as we had recently shown,
most cell sorters lead to cell shearing. Therefore, we used large particle fluorescence
activated cell sorting (LP-FACS), which is able to maintain cardiomyocyte shape and
viability. Here, I have performed single cell RNA-seq on CMs isolated at neonatal,
postnatal and adult stages (Figure 2.6) every 7 days following birth. Suraj Kannan
assisted with LP-FACS and prepared the single cell RNA-seq libraries. Dr. Brian Lin
performed the Langendorff heart perfusions.
Figure 2-6. Single cell RNA-seq experimental design. Mouse hearts were collected using
large particle fluorescence activated cell sorting. 96 CMs in each group were sequenced
except for P0 where 192 CMs were sequenced.
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Figure 2-7. A. t-SNE clustering showing CMs are heterogeneous. B. Trajectory across
pseudotime of CM maturation
Mouse myocytes were dissociated using MACS or Langendorff followed by sorting
by cell size using LP-FACS. t-distributed stochastic neighbor embedding (t-SNE)
clustering finds overlap between cells from different stages (Figure 2.7). This is
supported by uniform manifold approximation and projection for dimension reduction
(UMAP), which created clusters mostly based on timepoint with some intermixing
(Figure 2.10). This could indicate that transcriptome signatures are similar for
different stage CMs and that they mature at different rates. To track the trajectory
of maturation, we ordered CMs in pseudotime using Monocle. The maturation score,
which is normalized pseudotime, shows a jump from P7 to P14 (Figure 2.8). This is
the same timepoint difference that we dubbed the critical window from initial bulk
RNA-seq meta-analyses. Another key point was the heterogeneity as adult P28 CMs
were not fully heterogeneous. The variability in P14 and P21 timepoints is likely
caused by the number of cells sampled. This heterogeneity roughly matches the time
of flight measurements from LP-FACS, which show size shifts.
Next, I plotted the expression trends of genes known to change through maturation
(Figure 2.9). We see that structural genes key to contraction were upregulated
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Figure 2-8. A. Distribution of CMs for each timepoint based on maturation score.
Individual cells are overlaid. B. Time of Flight measurements for sequenced CMs.
including Tnni3, Myh6, and Myom2. Key calcium handling genes and ion channels
were also upregulated. As expected, cell cycle regulators driving proliferation were
downregulated.
The hypertrophy genes appear to be activated early on and taper off in expression.
To categorize the large changes that occur, gene ontology analysis of differentially
expressed genes was visualized (Figure 2.11), which indicated that the upregulated
genes are predominantly related to oxidative phosphorylation, fatty acid oxidation,
and muscle contraction.
We then wanted to determine whether mitochondrial genes, those in the mitochon-
drial genome, were also upregulated. Using a heatmap with hierarchical clustering,
(Figure 2.12). This could indicate an increase in the mitochondrial density.
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Figure 2-9. Gene expression over pseudotime for key cardiac genes. Genes were clustered
by function.
Gene Network analysis of maturation using single cell RNA-
seq
While the downstream gene changes associated with maturation have been documented,
the regulatory mechanism has not been determined. With the goal of determining
upstream regulators of postnatal CM maturation, I used IPA to predict drivers of
maturation. We first noticed that nuclear receptors were commonly activated in this
gene set (Figure 2.13). To narrow it down, we used a q-value cutoff of 10e-5 then
ordered them by the top p-value. PGC1α and PGC1β were among the top predicted
transcriptional regulators (Figure 2.14). This was supported by the upregulation of
mitochondrial and fatty acid oxidation genes.
To track the expression over development and maturation, we used quantitative
polymerase chain reaction (qPCR) and found that nuclear receptors increase in
expression (Figure 2.15). We collected hearts from embryonic (E9.5, E14.5, E18.5),
perinatal (P0), adolescent (P14), and adult (P28) mice. In addition, we used mouse
PSC-CMs collected at 10, 20, and 30 days after the beginning of differentiation. qPCR
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Figure 2-10. UMAP clustering shows cells segregate mostly be timepoint with some
mixing between groups indicating heterogeneity in maturation status
of the mRNA levels of these nuclear receptors in PSC-CMs showed that most increase
through differentiation except for Pgc1α and Pgc1β, which are misregulated. Looking
at these regulators in our scRNA-seq results, we see a 2 fold increase in Pgc1α and
Pparα expression over pseudotime (Figure 2.16). This could indicate that PGC1α and
PGC1β are activated in postnatal maturation and may be the cause of maturation
arrest that keeps PSC-CMs immature in vitro.
Discussion
I have shown CM maturation can be described by a temporal transcriptome atlas of
postnatal development. The gene expression signature can be used to determine the
pseudotime age, which corresponds with maturation state. This was completed in
high depth bulk RNA-seq and in high resolution single cell RNA-seq. Both datasets
showed an enrichment of metabolic, mitochondrial, and fatty acid oxidation genes
in the upregulated gene sets. These indicate that these processes transition during
postnatal maturation and support the known switch from glycolysis to oxidative
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Figure 2-11. Visualization of top GO terms generated for unregulated genes in scRNA-seq.
Mitochondrial, metabolism, and myofilament GO terms are present.
phosphorylation. KEGG pathway analysis showed the presence of genes related to
neurological conditions including Alzheimers and Parkinsons (Figure 2-2). This is
not due to neuronal contamination, but the links between mitochondrial function
and these diseases. This study provides the best temporal resolution of postnatal
maturation, which is key to PSC-CM maturation due to the maturation arrest at a
stage similar to neonatal CMs. Interestingly, we showed that there is a critical window
from P7 to P14. This jump in transcriptomic signature is accompanied by changes
in function and morphology including cell cycle cessation and hypertrophic growth.
External stimuli could cause this jump as cells respond to the increase in oxygen and
reactive oxygen species pushing a switch to fatty acid oxidation and causing oxidative
DNA damage slowing proliferation.33
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Figure 2-12. Heatmap showing expression of mitochondrial genes with hierarchical
clustering showing P28 and P14 having the highest mitochondria levels. All 7 expressed
mt-genes are upregulated.
In our GRN analysis and quantification of transcript levels, nuclear receptors
appear to be consistently activated, particularly the PPAR family including PPARα,
PPARδ, and PPARγ. Nuclear receptors affect gene regulation by binding an agonist
then enter the nucleus to bind DNA and regulate gene expression. Other nuclear
receptors have been shown to promote maturation including thyroid hormone receptor
and glucocorticoid receptor.1 PGC1α was also a top hit and is a co-activator of PPARs.
This is supported by knowledge of an energy metabolism switch early postnatally
that occurs 2-3 days after birth. NFkBIA was the top predicted upstream regulator,
but we decided not to select it for further investigation because its expression levels
are relatively flat through maturation. In addition, PGC1/PPAR have been better
characterized in the heart.
While bulk RNA-seq provides deep reads allowing us to track expression of low
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Figure 2-13. Nuclear receptors are activated in IPA of CM maturation. Red dots highlight
nuclear receptors, which mostly have positive activation z-scores.
count mRNA molecules, it has multiple drawbacks. Primarily, the combination of
multiple cell types. However, in PCA clustering, our isolated CMs, which the authors
of the study that collected this dataset estimated that they were at least 95% CMs,
were very close to the whole ventricle isolation. Therefore, there was a need for
single cell RNA-seq of postnatal maturation as this would provide insights into a
cardiomyocyte specific trajectory without fibroblast and endothelial cell contamination.
Our single cell results also depict the broad heterogeneity present in cardiomyocytes.
It appears that the rate of maturation differs. Future studies could see if the less
mature cells are located spatially in one region or if they are distributed throughout
the heart. Spatial RNA-seq, which became readily available following the completion
of this work, can be applied to create a map of maturation in the heart.
This used two types of gene regulatory network generation in IPA and WGCNA.
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Figure 2-14. PGC1α and PGC1β are among the top predicted upstream regulators of
CM maturation from IPA
There were similar results in the predicted upstream regulators list and the tran-
scriptional regulators that were present in the WGCNA modules that were positively
correlated with maturation. We used both because IPA uses known connections
between genes, while WGCNA infers all connections from the data provided. WGCNA
could determine co-regulated genes specific to CM maturation as genes can play
different roles in various cells.
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Figure 2-15. Heatmap showing nuclear receptor expression in both mouse hearts and
PSC-CMs. Increasing trends in expression occur in all nuclear receptors in the developing
hearts. Most increase in PSC-CMs except for PGC1 and PPAR showing dysregulation.




PGC1α in the heart
Background
PGC1
PGC1α is a transcriptional coactivator of many transcription factors that regulates
mitochondrial biogenesis.102 It was identified by a 2-hybrid screen in brown fat to find
binding partners of PPARγ since PPARγ is a target of drugs used to treat diabetes
mellitus. In muscle, PGC1 has been shown to interact with NRF-1 and TRB-1 to
regulate mitochondrial protein expression.103 PGC1α also binds ERRs, PPARα and
PPARδ to regulate glycolysis and fatty acid oxidation genes, specifically oxidation
enzymes and fatty acid transporters. ERR was recently shown to directly bind and
regulate cardiac contraction genes.78 ERR has also been shown to form a crosstalk loop
with PGC1 as there is an evolutionarily conserved binding site for ERR in the PGC1
promoter.104 PGC1 has a short half-life of 20 minutes due to PGC1α degradation by
the proteasome after ubiquitination.
PGC1α upregulates expression of the majority of the respiratory chain and ATP
complexes in addition to all of the enzymes in the citric acid cycle.105 Cardiac specific
overexpression of PGC1α leads to CMs packed with mitochondria and heart failure
due to disruption of myofibrils, but these changes were reversed when PGC1α was
repressed.104 Induction of cardiac PGC1α overexpression in adults did not lead to
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mitochondrial proliferation showing that it only drives mitochondrial biogenesis during
maturation.104 ERRα overexpression in rat neonatal CMs upregulates both glycolysis
and fatty acid oxidation. More than 98% of mitochondrial genes are in the nucleus,
but PGC1 also regulates the genes in the mitochondrial genome by inducing TFAM,
which drives mitochondrial genome transcription and replication, through NRF-1.105
PPAR
PPAR transcription factors bind DNA by heterodimerizing with retinoic acid-activated
receptors (RXRs).104 These upregulate metabolic and peroxisomal genes and have
been targeted for pharmacologically treating diabetes. PPARα is expressed in the
heart, brown adipose tissue, liver, and kidneys, which all use fatty acid as their energy
source. Cardiac overexpression of PPAR results in higher fatty acid oxidation and
lower glycolysis, but leads to lipotoxicity since fatty acid uptake was higher than
usage.105 PPARα knockout results in the opposite metabolic behavior with higher
glycolytic activity and lower fatty acid β-oxidation. PPARδ overexpression leads to
higher fatty acid oxidation and higher glucose utilization and does not result in heart
dysfunction.105
Regulators of PGC1α
PGC1 is regulated by phosphorylation of conserved sites. p38 phosphorylation can
prolong its halflife. AMPK directly phosphorylates PGC1α to increase its activ-
ity. However, Akt kinase can block PGC1α activition.105 Other post-translational
modifications such as acetylation and methylation are regulated by Sirt1 and Bcl3,
respectively.104 PGC1 activity is based on input from levels of ADP to ATP ratio,
stress, and the redox state. It can also sense calcium as it is regulated by calcineurin.105
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PGC1α in maturation
PGC1α null mice have no large changes in phenotype unless they are exposed to
exercise, fasting, or cold.106 This is thought to occur because PGC1β rescues function
due to an overlap in targets to compensate for the loss of PGC1α. Lai et al. generated a
double knockout of PGC1α and PGC1β.107 They found that cardiac specific PGC1α and
PGC1β deletion is neonatally lethal. Characterization of the hearts showed that there
was a maturation defect as myocytes were smaller with less mitochondria. Gene
expression comparison measured by RT-PCR showed that they had a fetal signature
as Myh6, Serca2a, and Pdk4 were down-regulated.107
Birket and colleagues set out to develop a model of heart disease by dysregu-
lating reactive oxygen species (ROS) levels in PSC-CMs. This study found that
PGC1α was required for mitochondrial capacity and electrophysiological function in
PSC-CMs by using PGC1α shRNA to knockdown PGC1α expression during cardiac
differentiation. They focused on the role of ROS levels in maturation and concluded
that PGC1α knockdown was beneficial to some aspects of maturation, which was
recapitulated by altering ROS levels.108
Recently, PGC1α has been shown to activate maturation in PSC-CMs, supporting
our initial findings. They used ZLN005, an activator of PGC1α, on PSC-CMs after
differentiation and found that it improved multiple aspects of maturation.109 Multiple
aspects of maturation were improved including calcium handling, sarcomere length,
and Connexin 43 gap junction development. As expected, metabolic maturation was
improved over control.109 PGC1α has been shown to be important in PSC-CMs and in
embryonic development, but its role in postnatal maturation has not been investigated.
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Mosaic knockouts
The first mosaic knockout system used to dissect gene function in the heart was the
CRISPR/Cas9 AAV-based somatic mutagenesis platform (CASAAV).110 A recom-
binant AAV expresses Cre in cardiomyocytes because it is under a cTnT promoter
then multiple single guide RNAs create indel mutations in the gene of interest.81 The
AAV is delivered to mice that have a loxP-stop-loxP-Cas9-P2A-GFP so that Cas9 is
Cre-activated with a fluorescent marker. This will create a loss of function mutation
in vivo. This was created to make it possible to generate a knockout without germline
engineering. An added benefit is that the AAV dose can be lowered to only create
mutagenesis in a fraction of the cells, which is important in the heart because cellular
defects can result in secondary effects. This allows us to study the gene quickly in a
cell autonomous manner. One limitation of this study is that the mutagenesis may
not lead to protein dysfunction. In a knock down of SRF, they found that mRNA
levels were approximately halved.
CASAAV has been used to study junctophilin-2 (JPH2) where a high dose resulted
in lethal heart failure, but a low dose did not affect heart function. Since loss of
function was lethal, it had not been previously studied in postnatal hearts. The
study also looked for other genes that would affect T-tubule development, which was
visualized by fluorescent staining. This group has gone on to generate knockouts of key
cardiac genes Ryr2, Nkx2-5, Mef2c, Gata4, Tbx5, and Tead1 including to see if they
influence cardiac maturation. They found that SRF plays a critical role in postnatal
maturation in a cell autonomous manner.82 A cardiac conditional knockout led to
lethal dilated cardiomyopathy, showing CASAAV’s ability to assess the relevance of
genes that could not have been studied previously. Vandusen and colleagues then
combined CASAAV with a library approach to knock out all genes in a screen for
cardiac maturation. They found epigenetic regulators RNF20/40 to be required for
postnatal maturation. Others have used CASAAV to rescue CMs with a hypertrophic
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phenotype and tested regulators of heart failure.111
Since PGC1 had been identified as an upstream regulator of CM maturation, we
wanted to determine if it was required for CM maturation. We used a conditional
mosaic knockout to determine the cell autonomous role of PGC1. Cell size, contractility,
and transcriptomic maturation were investigated to assess maturation state.
Materials and Methods
Fuzzy clustering and pathway analysis
Monocle2 was used to cluster and order cells for preparing trajectories.101 Pseudotime
was normalized for the maturation score. Fuzzy clustering was done with mFuzz
R package and visualized with ggplot2 and coloring package.112 For Gene Ontology,
PantherGO provided statistics and top enriched GO terms.95 Visualization of top
selected GO terms was made with a custom R script using ggplot2. Codes used can
be found in appendix ii.
Animal Handling and Genotyping
PGC1α/β flox mice were received from the Jackson Laboratory and then bred to
produce knockout lines. All protocols involving animals followed US NIH guidelines
and were approved by the animal care and use committee of the Johns Hopkins Medical
Institutions through the JH Research Animal Resources facility. Genotyping was
performed by cutting tails at 3 weeks after birth. Mouse were ear tagged for tracking.
DNA was isolated using the Phire Animal Tissue Direct PCR Kit (ThermoFisher
Scientific). The mouse tail tissue was added to 19.5 µL of Dilution buffer and 0.5 µL of
DNA Release additive. Samples were incubated at room temperature for 10 minutes
then 98 C for 5 minutes. A 10 µL polymerase chain reaction (PCR) was prepared by
adding 0.25 µL of 10 uM primers, 0.5 µL of samples, 5 µL of GoTaq Green Master
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Mix (Promega), and 4.5 µL of ultrapure water. They were then thermocycled for 35
cycles for 5 second at 98 C and annealed for 30 seconds at 59 C then extended for 30
seconds at 72 C. Primers used can be found in appendix i and were designed by the
line generators and obtained from the Jackson Laboratory.
Adeno-associated virus
AAV9-cTnT-iCre was obtained from Vector Biolabs. It was diluted in cold PBS and
stored on ice until injection. Each P0 pup was injected subcutaneously. Mice were
anesthetized prior to injection. Mice were monitored following injection and then
returned to the cage with the mother.
Library Preparation and Sequencing
Single cell RNA sequencing was performed as previously described in the Chapter 2
methods.
Dissociation of myocytes
A langendorff setup was used to perfuse hearts with Type II Collagenase and Protease
digestion buffer over 9 minutes as previously described in Chapter 2. Cells were
centrifuged at low speeds then resuspended in Tyrodes Solution containing bovine
serum albumin. In 10 minute increments with a change of 0.25 mM calcium, CMs
were stepped up to 1 mM calcium in a tyrode’s solution.
Immunofluorescent Staining
Hearts were fixed overnight in 4% paraformaldehyde at 4 C. They were then transferred
to a 30% sucrose solution overnight at 4C. Hearts were embedded in OCT and flash
frozen using dry ice and methyl butane then stored at -80 C until sectioning. A
cryotome was used to prepare 8-12 um thick slices that were mounted onto glass slides.
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Dissociated CMs were cultured on glass coverslip in DMEM media containing FBS
and blebbistatin to prevent contraction for 45 minutes then fixed with 4% PFA for
10 minutes at room temperature. Once fixed, they were stored in phosphate buffer
solution (PBS) overnight at 4 C. Heart slices were rehydrated in PBS then blocked and
permeabilized in PBS containing fetal bovine serum, bovine serum album, and 0.1%
triton X-100 for 1 hour. They were treated with the mouse anti α-actinin primary
antibody diluted 1:200 overnight at 4 C on a rocker. Slides were washed in PBS 3
times for 5 minutes. The goat anti mouse alexa fluor 488 secondary antibody diluted
1:500 was applied for 1 hour at room temperature. Following 3 PBS washes for 5
minutes, samples were counterstained with wheat germ agglutinin (WGA) and DAPI
to visualize the nuclei and plasma membranes. They were briefly dried and covered
with prolong diamond and mounted on a glass slide. They were imaged using confocal
microscopy with a 63x oil objective on a Leica SP8. Image quantification was blinded
and performed with ImageJ FIJI.
Calcium Handling and Contractility
Cells were sorted into a 24 well plate with laminin-coated glass slides. They were
then loaded with Fura2AM Calcium dye (Fura2 LeakRes from Abcam) for 10 minutes.
They were then tracked with IonOptix imaging system (Myocam) then analyzed
with IonWizard software. CMs were paced at 1 Hz under an inverted microscope
(Nikon, TE2000). The sarcomere shortening and calcium transient measurements were
completed at 37 C in a Tyrode’s solution with 1mM calcium and 0.01% DMSO. The




ANOVA with post hoc Bonferroni tests were used to determine significance in compar-
ison of 3 or more groups. Statistics were completed using R or excel analysis toolpak.
Student’s t-test was used for a comparison of 2 groups.
Results
Figure 3-1. Schematic showing PGC1 floxed mice with a Rosa locus TdTomato reporter
were injected with AAV9 on the day of birth at low doses to form a mosaic. Cardiomyocytes
will be isolated on P28 for morphological measurements, transcriptomic measurements,
and function assays
Figure 3-2. Confirming the PGC1 knockout. a. Primer design for determining efficiency
of excision at PGC1a locus. b. Relative levels of PGC1a cCDNA in control and RFP
positive CMs. c. Relative levels of excised cDNA. d. Primer design for assessing PGC1b
levels. e. Relative levels of excised PGC1b (n=2 mice in each group)
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Figure 3-3. Confocal images of fluorescently immunolabeled a-actinin (green), TdTomato
(red), and nuclei (blue) in sections and dissociated CMs.
Generation of PGC1α/β conditional mosaic knockout
We hypothesized that PGC1 is a key driver of maturation based on the results of
the time series analysis of transcriptomic maturation. Global knockout or cardiac
conditional knockout of PGC1α and PGC1β results in lethality within 24 hours of
birth.107 Knockout of PGC1α or PGC1β leads to a mild phenotype as they compensate
in loss of function of the other. To test our hypothesis, we made conditional mosaic
knockout (cmKO) mice to study the postnatal role of PGC1 in maturation. To do
this, Pgc1α flox/flox Pgc1β flox/flox mice with a Rosa locus lopx-stop-loxp tdTomato
reporter were injected on P0 with AAV9-cTnT-iCre (Figure 3.1). Danielle Rigau
assisted in animal work to create the Pgc1 floxed mice. This leads to expression
of Cre recombinase only in cardiac myocytes. The AAV9 dose was titrated to 2e10
GC per mouse to result in 5-10% RFP positive cells in the heart so that the cell
autonomous effects could be investigated. LP-FACS was then used to sort single cells
by fluorescence and size for use in assays of morphology, transcriptomics, and function.
45
Figure 3-4. Violin plots showing the distribution of CM areas at P7 (WT n=44, cmKO
n=11), P14 (WT n=90, cmKO n=49), and P28 (WT n=522, cmKO n=132). ANOVA
with post hoc Bonferroni tests were used. P-value *<0.05 **<0.01 ***<0.001.
The virus was injected on P0 with functional tests run on P28 CMs. Morphological
and transcriptomic analyses were run every 7 days from P0 to P28.
To confirm that the sorted RFP+ myocytes lack intact PGC1α and PGC1β, custom
qPCR primers were designed (Figure 3.2) to quantify levels of normal and excised
PGC1α/β. We found that the excised mRNA is much higher in our RFP+ cells and
normal PGC1α mRNA is knocked down. Previous studies found comparable knockout
efficiency using a CRISPR/Cas9 knockout system.
Hypertrophy resulting in an increased size is a hallmark of CM maturation. CMs
were dissociated and imaged with fluorescence microscopy (Figure 3.3). We measured
the cell size of our PGC1 cmKO RFP+ myocytes and found that size was significantly
reduced at P7, P14, and P28 (Figure 3.4). The hypertophy is not just delayed, but
arrested as later adult stages still showed significantly smaller myocytes. To rule out
affect of the AAV9-cTnT-Cre virus on maturation, we injected it at P0 into Rosa
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Figure 3-5. Injection of AAV9-cTnT-Cre into P0 mice with only a Td-Tomato reporter
show no significant change in cell size at P28. n.s=p-value>0.05. Control n=87, Td-tomato
n=26
tdTomato mice and found no significant change in cell size (Figure 3.5). Matthew
Miyamoto took images of the PGC1 cmKO CMs. which were quantified by Sandeep
Kambhampati.
Next, we looked into the effect of PGC1 cmKO on CM contractility. Video
microscopy was used to track sarcomere shortening and contraction parameters. We
see that fractional shortening and contraction velocity are significantly lower (Figure
3.6). This indicates that force produced by CMs is lower in PGC1 cmKO cells. Dr.
Brian Lin collected data on Calcium handling and sacromere shortening and was
blinded to experimental groups. For this analysis, 1-3 CMs were used from each
isolated heart from 11 P28 mice for each condition. Other parameters of contraction
were not significantly different including tau, return velocity, time to 90% of Baseline,
and Peak Height (Figure 3.7). Calcium handling was also affected as the peak height
and departure velocity were lower for the PGC1 cmKO (Figure 3.6). Other parameters
quantifying the calcium transient showed differences, but were not significant including
47
Figure 3-6. Contractility and Calcium Handling of P28 PGC1 cmKO CMs. a. combined
shortening traces of control and PGC1 cmKO CMs. b. Fractional shortening c. Contraction
velocity. d. combined calcium transient traces. e. Peak Height. f. Departure velocity.
Student’s t-test was used. *=p-value<0.05 WT n= 9, cmKO n= 13
tau, baseline calcium, and return velocity (Figure 3.7). However, time to 90% of
Baseline was much slower for PGC1 cmKO. These results indicate that PGC1 is
required to develop mature contraction and calcium cycling functionality.
PGC1 regulates genes in hypertrophy, calcium handling, and
mitochondrial activity.
Since PGC1 was shown to play a key role in functional and morphological maturation,
we investigated its role in transcriptional regulation. In the same manner as the
functional study, RFP+ PGC1 cmKO cells from P7-P28 were collected for single cell
RNA-sequencing. Cells were then ordered into a trajectory using Monocle (Figure 3.9).
The pseudotime was converted into a normalized maturation score and clearly shows
that there is a significant difference at all time points. Therefore, PGC1α/βcmKO
results in a less mature state (Figure 3.9). While this brings up the question of whether
maturation is stopped or slowed, cell size does not continue to increase as P56 PGC1
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Figure 3-7. P28 PGC1 cmKO CM shortening (a-d) and calcium transient parameters
(e-h). a. Tau b. Peak height c. return velocity d. time to baseline 90 e. Tau f. baseline
calcium g. return velocity h. time to baseline 90. Student’s t-test or Mann-Whitney-
Wilcoxon test were used. ***=p-value<0.001, n.s.=p-value>0.05 WT n= 9, cmKO n=
13
cmKO myocytes do not catch up to the control CMs.
To determine how cardiomyocyte maturation signaling is perturbed by the loss
of PGC1, we used fuzzy clustering to group genes by their expression pattern over
time. The top upregulated and downregulated clusters were selected from each group
(Figure 3.10). When comparing PGC1 cmKO with WT CMs, we see that less than
7.6% of upregulated genes and 16.2% of downregulated genes overlap. This shows
that the gene regulatory network of the PGC1 cmKO CMs is disrupted. We used GO
term enrichment to characterize the expression changes over time. We see that fatty
acid oxidation and cardiac contraction terms were enriched in the downregulated gene
while metabolic processes were upregulated (Figure 3.11). This finding confirms the
role of PGC1 in mitochondrial biogenesis and unveils a possibly new role in regulation
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Figure 3-8. Trajectory containing both control and PGC1 null CMs from P0, P7, P14,
P21, and P28.
of other aspects of CM maturation.
Discussion
Here, we present the first cmKO using the Cre-lox system to knock out function
of PGC1. This is more thorough than CRISPR-Cas9, which may have unintended
off target genomic disruption. In addition, the indel mutagenesis may not lead to
a knockout of the protein, but a change in function. PGC1 conditional knockouts
had previously been generated and led to neonatal death due to heart dysfunction.
However, PGC1’s postnatal role had not been investigated. Using the cmKO system,
we were able to generate a knockout of both PGC1α and PGC1β after birth. A
strength of this experimental setup is that it control CMs come from the same mouse
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Figure 3-9. Maturation score by timepoint and condition showing cmKO cells are
transcriptomically immature
heart. This is important as it may ameliorate batch effects caused by dissociation,
sorting, and sequencing. Since PSC-CMs arrest at a late embryonic to neonatal stage,
we were most interested in the P0 to adult development. The mosaic knockout allows
us to determine its role during the critical window previously identified. We decided
to deliver the AAV9-cTnT-Cre at P0 as there may have been challenges in dosing,
consistency, and efficiency when attempting to deliver the virus through the pregnant
mouse.
Our measurements of PGC1 cmKO indicated that PGC1 is required for hypertrophy.
This was initially surprising since PGC1 is a co-activator of transcriptional activators
of mitochondrial genes. Although we were not able to quantify the volume change,
we did see that area was significantly reduced. We confirmed that this was not due
to off target effects from the AAV9 vehicle. It also resulted in functional changes
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Figure 3-10. Fuzzy clustering of gene expression patterns in control and cmKO. Upregu-
lated clusters and down regulated clusters were selected for each group.
to calcium handling and contractility. Knockout of PGC1 leads to disruption of the
gene regulatory network of maturation. This indicates that it is key to development.
When comparing the differentially expressed genes, we see that it includes metabolic
and fatty acid oxidation genes, as expected, but also includes contraction genes. This
indicates that PGC1 may directly or indirectly regulate non-metabolic aspects of CM
maturation.
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Figure 3-11. GO terms for differentially expressed genes from a comparison of control
and PGC1a cmKO separated into up and down regulation
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Chapter 4
PGC1a promotes maturation in
PSC-CMs
Background
Cardiomyocyte maturation is a leading obstacle holding them back from entering
the clinic or for widespread use in pharmacological testing and disease modeling.
Many strategies have been used to improve including electrical stimulation, stretching,
culture on a surface, co-culture with fibroblasts. However none of these alone or in
combination have yielded mature myocytes. Therefore, we aim to use our new insight
into the gene regulatory network of CM maturation and test the idea that PGC1
activation can promote maturation. We propose that PGC1α is a driver of maturation
and will test this in immature PSC-CMs. Small molecules have previously been
used to improve maturation as T3 and Dexamethasone lead to PSC-CM hypertrophy,
increased contractility, and other aspects.47,48 A combination of these with culture on
a matrigel mattress was able to form t-tubules in PSC-CMs. However, when cultured
on matrigel coated tissue culture plastic, a network of t-tubules does not form so our
expectation is not that this will produce fully mature myocytes. Future studies could
investigate combining this with 3D tissue culture, but that is outside of the focus of
this study.
PGC1 had been identified as a predicted upstream regulator and was confirmed
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as required for CM maturation. Our next goal was to see if it had the ability to
improve PSC-CM maturation. We used genetic and small molecule techniques to
activate PGC1. We quantified the effect of PGC1 agonist treatment on cell size, force
production, and metabolic capacity.
Materials and Methods
Stem cell culture and differentiation
Human (H9) and mouse embryonic stem cells (E14) were differentiated into cardiomy-
ocytes. All Johns Hopkins Medical Institutions and US NIH guidelines for culture and
disposal of stem cells were followed. Mouse ESCs were maintained in a flask coated
with 0.1% gelatin for 5 minutes. Stem cell maintenance media (GMEM + 10% FBS
with 1 uM PD98059, 3 uM CHIR99021, Glutamax 1:100 (Thermo Fisher Scientific),
non-essential amino acids 1:100, and sodium pyruvate 1:100). PSCs were differentiated
into cardiomyocytes by forming emrbyoid bodies over 48 hours by plating 80,000 cells/
mL into an uncoated 25 cm plate in differentiation medium (75% IMDM, 25% Ham’s
F12 (Cellgro), B27 without vitamin A, N2, BSA, glutamax, penicillin/streptomycin,
L-ascorbic acid, and α-monothioglycerol. After the 48 hour embryoid body formation,
the media was changed to differentiation media containing Bmp4 and Activin A.
Precisely 48 hours later, cells were dissociated and plated onto a gelatin-coated surface
in differentiation medium with XAV939 added (Sigma). PSC-CMs generally start
being 7-8 days after emrbyoid body formation and were then selected by using a 4mM
lactate DMEM media without glucose or 1 µM puromyocin. PSC-CMs were replated




2% FA in 0.075 cacodulate with 5 mM MgCl2 was used to fix D30 PSC-CMs overnight
at 4C. Samples were then rinsed with a 3% sucrose buffer 3 times for 15 minutes then
treated with 1.5% KFeCN6 and 2% osmium at 4C for 2 hours. They were then rinsed
with 3% sucrose and 0.1 M maleate buffer at pH 6.2 for 10 minutes three times. They
were then placed in 2% UA in sucrose/maleate buffer for 1 hour in the dark. They
were dehydrated using an ethanol ladder starting at 30% and going to 100% ethanol
for 5 minutes in each bath. Samples were then treated with propylene oxide followed
by an EPON resin with the catalyst overnight while rocking. Next, samples were
treated with EPON resin and catalyst for 2 hours then put in an oven for 48 hours at
60 C. A Diatome diamond knight was used to cut sections and then collected on a 2x1
mm formvar-coated slot grid. They were stained with uranyl acetate then lead citrate.
To image the slices, a Hitachi H-7600 TEM operating at 80 kV was used. Then an
AMT XR-50 CCD was used to digitize the images.
Mitochondrial functional assay
A Seahorse XFe96 Analyzer was used to measure respiration rates. Before measurement,
CMs were plated in a 96 well XF96 Cell Culture Microplate (ALigen Technologies)
at 1.5e4 cells per well. They were cultured for 72 hours. Prior to the assay, medium
was changed to RPMI without phenol red and sodium pyruvate was added. Cells
were cultured in an incubator without supplemented carbon dioxide for 1 hour. Using
the Mito Stress Test protocol and Seahorse Extracellular Flux Assay Kit, OCR was
measured with inhibitor final concentration of 2.5 uM for Animycin A, Oligomycin,
and Rotenone and 1 uM for FCCP.
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Immunostaining and Confocal Imaging
PSC-CMs cultured on gelatin coated coverslips were rinsed with PBS then fixed in
4% paraformaldehyde for 10 minutes. They were rinsed with PBS for 5 minutes 3
times then stored in excess PBS at 4 C until staining. Samples were rinsed 1 time
with PBS for 5 minutes then 0.2% Triton X-100 was added for 10 minutes. They
were rinsed 3 times then 1% Bovine Serum Albumin and 1% Fetal Bovine Serum was
added for 1 hour. Primary antibody was added to 1% Bovine Serum Albumin and
1% Fetal Bovine Serum at dilution of 1:200 then stored on a rocker overnight at 4 C.
Samples were removed and rinsed 3 times with PBS for 5 minutes. The fluorescently
conjugated secondary antibody was diluted 1:500 in PBS then placed on the rocker for
1 hour at room temperature. This and all future steps were conducted without light
by placing the dish in a drawer or under aluminum foil to prevent photobleaching.
Samples were rinsed 3 times for 5 minutes in PBS. Samples were counterstained with
DAPI diluted 1:2000 and WGA diluted 1:100 in PBS. They were rinsed 3 times in PBS
for 5 minutes each and placed on a glass slide with a droplet of ProLong Diamond.
Coverslips were sealed using clear nail polish. A Leica SP8 was used to image samples
using photon-counting mode with a 63x oil immersion objective.
Contractility experiments
Human PSC-CMs were analyzed using an high throughput automated calcium handling
system in collaboration with the Colas laboratory at Sanford Burnham Prebys Medical
Discovery Institute. Video imaging was analyzed for calcium transients.
Statistics
ANOVA with post hoc Bonferroni tests were used to determine significance in compar-
ison of 3 or more groups. Statistics were completed using R or excel analysis toolpak.
Student’s t-test was used for a comparison of 2 groups.
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Results
Figure 4-1. PGC1α overexpression increases PSC-CM size. Student’s t-test was used.
*=p-value<0.05. Control n=55, PGC1α-OE n=46
Figure 4-2. PSC-CM differentiation timeline. PSCs are cultured in 2i media. Embryoid
bodies form over the first two days. Media is changed and supplemented with BMP4 and
Activin A. Cells are dissociated and replated onto gelatin coated tissue culture plates. After
beating occurs, puromycin or lactate selection is performed. Agonists or DMSO control
are added to cell starting on d10.
PGC1/PPAR agonists increase size
Since PGC1 is misregulated in PSC-CMs with lower expression levels and it is required
for aspects of CM maturation, we looked into the ability of activation of PGC1α in
PSC-CMs to promote maturation. We overexpressed GFP-PGC1α in PSC-CMs and
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Figure 4-3. Staining of sarcomeres show better organization and elongation of agonist-
treated PSC-CMs. Insets show better alignment of parallel myofilaments.
found a significant increase in the area (Figure 4.1). Therefore, PGC1α is involved
in growth and hypertrophy of developing CMs. Since overexpression under a CMV
promoter can lead to non-physiologically relevant levels, we used pyrroloquinoline
quinone (PQQ) to activate PGC1α expression. Dr. Emmanouil Tampakakis performed
the hPSC-CM differentiation and treatment.
Hypertrophic growth was observed in the PQQ-treated d30 myocytes (Figure 4.2).
We found that WY14643, a PPARα agonist, was also effective in increasing cell size
and sarcomere organization in blind measurements at d30 following 20 days of agonist
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Figure 4-4. Cell area of PSC-CMs treated with PGC1/PPAR agonists. ANOVA followed
by post hoc Bonferroni tests were used. *=p-value<0.05, **=p-value<0.01. Control
n=192, PGC1α agonist n=162, PPARαn=119
treatment (Figure 4.3, 4.4). PSC-CMs were treated with the agonists from d10 to
d30. Cell size was assessed by immunofluorescent staining of α-actinin and WGA,
a cell surface marker, then imaged using confocal microscopy. Matthew Miyamoto
differentiated and maintained most mPSC-CMs used in these experiments.
PGC1/PPAR activation improves mitochondrial function and
contractility
One of the most important aspects of CM function is the contractility. To see if
treatment with PGC1 and PPARα agonists resulted in increased force production, we
used Fourier transform traction force microscopy (Figure 4.5). PSC-CMs treated with
PQQ, WY14643, or a combination were compared to a DMSO control by replating
them onto polyacrylamide gel with a Young’s Modulus of 8 kPa and culturing 3 days
before imaging on d30. The polyacrylamide gel stiffness was selected because it is close
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Figure 4-5. Heatmap showing force produced by PSC-CM and measured by Fourier
transform traction microscopy
to that of the heart. High speed imaging was used to calculate the force produced
as they deformed a gel containing fluorescent beads. Here, we see that PGC1α and
PPARα increase force and that the combination results in less heterogeneity (Figure
4.6). These results indicate that PGC1/PPAR may be a driver of PSC-CM maturation.
This work was completed in collaboration with Sam Paek and Dr. Steven An.
We were also interested in looking at the mitochondrial development since PGC1α is
the master regulator of mitochondrial biogenesis. Transmission electron microscopy
was used to quantify mitochondrial density of d30 PSC-CMs where we found that it
more than tripled with treatment of PGC1α and PPARα agonists (Figure 4.7).
To characterize this mitochondrial function, we used a Seahorse analyze that
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Figure 4-6. Force produced by agonist PSC-CMs show an increase in contraction force
measured. ANOVA followed by post hoc Bonferroni tests were used. ***=p-value<0.001.
Control n=5, PGC1α agonist n=6, PPARα agonist n=6, Combination n= 6
measures oxygen consumption rate. This provided the basal and maximal respiration
of d30 mouse PSC-CMs treated with PGC1α or PPARα agonists or a combination
of both. Maximal OCR normalized was significantly higher than the control cells
(Figure 4.8). This indicates that they have more metabolic mitochondrial capacity
consistent with higher mitochondrial density and large cell size. Since this works
in mouse PSC-CMs, we wanted to confirm that this phenomenon was conserved in
human PSC-CMs. We performed immunostaining for α-actinin and saw a larger cell
size (Figure 4.9). Therefore, PGC1α ’s role in maturation may be similar in rodents
and humans.
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Figure 4-7. a. Electrion microscopy images of sarcomeres (black arrows) and mitoochon-
dria (white arrows). b. Mitochondrial density from image analysis. Student’s t-test was
used. ***=p-value<0.001. Control n=9, PGC1/PPAR agonists n=14
Discussion
This shows that PGC1α activation promotes PSC-CM maturation. PGC1α has been
characterized as a driver of mitochondrial biogenesis and is perinatal lethal. Since the
heart forms normally, but cannot keep up with the need for cardiac output due to poor
CM function, the defect is likely a cell autonomous one. As hypothesized, mitochondrial
density was increased 3-fold. While mitochondrial maturation and ultrastructure
was not investigated, oxidative phosphorylation capacity was measured through
respiratory rate, which was significantly higher in those treated with PGC1α and
PPARα. PGC1α activation resulted in increased cell size. This may be in part due to
the increased energy produced as mitochondrial content provides a surplus of ATP. In
addition, the higher mitochondrial content could take up more volume leading to larger
cells. However, in a CASAAV knockout of mitofusin1 and mitofusin2, CM volume
may be independent of mitochondrial function.82 It is possible that PGC1α regulates
expression of genes associated with hypertrophy.
PGC1α activates mitochondrial biogenesis and, importantly, increases contractile
force. Our analysis of contractility through traction force microscopy showed that
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Figure 4-8. a. Oxygen consumption rate during Seahorse XFe96 stress test. b. Maximum
OCR rate for treated PSC-CMs. ANOVA followed by post hoc Bonferroni tests were used.
****=p-value<0.0001. Control n= 17, PGC1α agonist n=18, PPARα agonist n=18
individual cells more than double in force production. This finding shows that
PGC1α improves non-metabolic aspects of maturation. Combined with our data
showing that calcium handling is altered in the PGC1 cmKO CMs, PGC1 could be a
driver of multiple aspects of maturation. It is possible that they are intertwined and
increasing one aspect of maturation leads to an increase in others, but this has not
been demonstrated. Therefore, PGC1 could transcriptionally regulate other aspects
of maturation through a mitochondrial independent mechanism.
Since PGC1α co-activates PPARα and PPARα activation also improves maturation,
it could be that PGC1α predominantly acts through the activation of PPARα in
promoting non-metabolic maturation. It is known that PPARα leads to upregula-
tion of fatty acid oxidation genes and peroxisomal genes, but it is not known how.
PPARα is a nuclear receptor that binds fatty acids. Multiple reports have shown that
supplementing media with fatty acids promotes maturation in PSC-CMs. This could
provide insight into the signaling mechanism responsible for fatty acids driving matu-
ration. However, it is not well understood how fatty acid activation alters sarcomere
organization, binucleation, and electrophysiological properties of PSC-CMs.
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YAP in cardiomyocytes and in growth
Yes-associated protein (YAP) is a transcriptional co-activator that is important for
growth and proliferation. It is inactivated through phosphorylation by the Hippo
kinase cascade, which regulates organ size. YAP binds with TEAD1-4 to bind DNA
and drive cell cycle progression. YAP/TAZ are able to act as mechanosensors that
regulate single cell volume through maintaining intracellular cytoplasmic pressure.113
Perez-Gonzalez et al. showed that this is independent of mTor, another regulator of
cell size.
Altering Hippo/YAP signaling has been a therapeutic target to regenerate cardiac
tissue through activating the CM cell cycle.114 YAP has been shown to directly regulate
a subunit of phopshoinositol-3-kinase in cardiomyocytes.115 This shows that YAP can
activate the PI3K-Akt pathway to promote cell division through blocking GSK-3β and
increasing β-catenin levels.116 YAP has also been shown to regulate proliferation in
PSC-CMs based on the density of cell culture.117 FAT4 regulates YAP1 control of
heart growth as a part of the non-canonical Hippo pathway.118
Hippo/YAP controls the size of the organ by regulating cell proliferation and death.
The adult heart growth occurs by hypertrophy rather than proliferation and this process
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is influenced by YAP activation. It has been proposed that it is dose dependent where
low levels drive hypertrophy and higher levels promote proliferation.119 YAP’s control
of hypertrophy was investigated through a cardiac specific heterozygous knockout in
TAC mice which lead to lower levels of hypertrophy and higher levels of fibrosis and
apoptosis.120 Inhibition of YAP in diabetic mice with TAC prevents the development
of heart failure.121 Hippo/YAP have been implicated as a mediator of physiological
cardiac hypertrophy following exercise in adult rats.122 In addition to regulation of
proliferation and growth, YAP/TAZ may regulate metabolism and mitochondrial
function, particularly in the metabolic remodeling in heart failure.123
Splicing in cardiac development
RNA splicing is the removal of introns from pre-mRNA and joining together of exons
to form the mature mRNA.124 Alternative splicing is the removal of exons in different
combinations resulting in many mature mRNAs from a pre-mRNA. The majority
of genes have been shown to undergo alternative splicing. This highly conserved,
post-transcriptional process is performed by the spliceosome, which is a complex made
of small nuclear RNAs (snRNAs) and proteins that recognize splice sites to position
and catalyze the cutting. Splicing occurs in the nucleus by the major spliceosome and
in the cytoplasm by the minor spliceosome, which recognizes different introns and
is associated with alternative isoforms.124 An array of different types of splicing can
occur including skipping exons, removing mutually exclusive exons, retaining introns,
and editing exons.
Splicing has been shown to play a key role in heart development and disease.
Kalsotra and colleagues used splicing arrays to find 63 alternative splicing events in
heart development linked to the CELF protein that is later downregulated 10 fold by
adult timepoints. RNA-binding motif protein 24 (Rbm24) has been shown to regulate
cardiac splicing events. Rbm24 knockout is embryonic lethal and null mice have struc-
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tural heart defects with CMs exhibiting no sarcomerogenesis.125 Postnatal maturation
also includes alternative splicing changes as SFRS1 splices calmodulin-dependent
protein kinase, cardiac troponin T, and LIM-domain binding3. A conditional knockout
of SFRS1 resulted in death 6-8 weeks after birth as hearts dilated cardiomyopathy.
Alternative splicing has been found to cause some myotonic dystrophies so therapeutics
have emerged as a way to skip exons. SRSF2 is another protein where cardiac-specific
null mice develop dilated cardiomyopathy, but do not die as a result.125 SRSF2 is
thought to splice the ryanodine receptor 2 postnatally. Aberrant splicing in car-
diomyocytes has been shown to be both the cause of disease and the consequence of
other mutations. Spliceosome component mutations can lead to muscular atrophy.
Mutations in the splice sites can also lead to disease as heart disease can be caused by
a cardiac troponin T 2 or myosin binding protein-C splice site mutation. In addition, a
stressed heart can switch to alternative splicing of cardiac genes into the fetal isoforms
including myomesin and titin. Next-generation sequencing has unleashed the potential
to study alternative splicing.126
SF3B1 and SF3B2
The SF3B complex is part of the spliceosome and combines with U2 small nuclear
ribonucleoprotein particle (snRNP). SF3B recognizes branch point sequences, which
mark the 3’ end of an intron and are used for to remove introns. It also has a
role independent of U2 snRNP in exporting RNA by recruiting the transcription-
export complex.124 Splicing factor SF3B2 (also known as SAP145 and SF3b145) is
highly conserved and has not been studied in the heart. SF3B2 has been shown to
create a splice variant of the androgen receptor.127 This was demonstrated in prostate
cancer cells, but other targets of SF3B2 are unknown. Photoactivatable ribonucleoside-
enhanced crosslinking immunoprecipitation (PAR-CLIP) was used to show that SF3B2
binds exons that are included and introns that are excluded from the androgen receptor
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variant mRNA. SF3B2 can be altered through dimethylation of arginine residues by
protein arginine methyltransferase 9 (PRMT9) to create alternative splicing.128 SF3B2
has been implicated in regulation of cell cycle progression as the viral protein R (VPR)
of human immunodeficiency virus type 1 induces cell cycle arrest.129 This occurs by
VPR binding SF3B2 to prevent formation of the SF3B complex and depletion of either
SF3B2 or SF3B4 results in cell cycle arrest.
SF3B1, another member of the 7 component SF3B complex, has been linked
to hypoxia-inducible factor 1a (HIF1a) and an alteration of fructose metabolism in
heart disease.130 HIF1a drives the transcriptional response to low oxygen levels that
occur in heart failure. SF3B1 was identified as a target of HIF1a by its hypoxia
response element in its promoter region. Mirtschink and colleagues showed that SF3B1
alternatively splices ketohexokinase (KHK), a fructose-metabolizing enzyme, from
KHK-A to the high fructose affinity KHK-C. Fructose metabolism initiated by hypoxia
leading to hypertrophy and diastolic dysfunction. Knockdown of SF3B1 via shRNAs
in a transverse aortic constriction (TAC) treated mouse heart prevented the pathologic
cardiac hypertrophy by preventing the switch to the KhK-C isoform.130 It appears that
SF3B family members may regulate key aspects of maturation including proliferation
and metabolism.
In this chapter, we wanted to identify the mechanism of how PGC1 promotes
non-metabolic aspects of maturation. Based on gene expression in maturation, we
examined the role of YAP1 in PGC1’s regulation of hypertrophy. We used a high
throughput screen of putative PGC1 targets by measuring the effect of siRNAs on




Hearts from P7 mice were isolated, rinsed in PBS and minced following the protocol
from van den Boogaard et al. They were fixed in 1% paraformaldehyde crosslinking
buffer for 15 minutes then transferred to a crosslinking buffer with 125 mM glycine for
5 minutes.131 Samples were washed twice with ice cold PBS then frozen and stored at
-80 C. They were thawed and placed in 1 mL PBS on ice then homogenized at 20,000
rpm for 30 seconds until no chunks were visible. Samples were centrifuged at 2300 x g
for 5 minutes at 4 C. The supernatant was discarded then resuspended in 1 mL of lysis
buffer with protease cocktail for 1 hour at 4 C then ground with dounce homogenizer
20 times. DNA was fragmented using sonication for 20 cycles of 30 seconds on and
30 seconds off at 50% power. Shearing efficiency and distribution of read size was
optimized through visualization on a 2% agarose gel. Each sample containing 3 P7
ventricles were diluted to 3 mL.
Contraction and Calcium Single Cell Analysis
The contraction kinetics of cardiomyocytes were measured by tracking the disturbance
in the patterns of calcium oscillation. This was observed with Ca2+-sensitive fluorescent
dyes that were used to measure the effect on cardiomyocyte beat rate and pattern.
The effect of siRNAs and small molecules on CM beating rate and contraction were
measured by tracking calcium oscillation with a custom module in MetaXpress. The
traces are the contraction pattern for a single representative cell. The contraction
intensities were normalized to control for each siRNA-treated sample. We used two
separate experiments to generate CM contraction data.
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Statistics
ANOVA with post hoc Bonferroni tests were used to determine significance in compar-
ison of 3 or more groups. Statistics were completed using GraphPad Prism software
(2019) or excel analysis toolpak. Student’s t-test was used for a comparison of 2 groups.
Unpaired nonparametrix Kolmogorov-Smirnov test was used in the screen.
Results
Figure 5-1. Brightfield and fluorescent imaging of dissociated YAP1 cmKO CMs
Figure 5-2. Image analysis of YAP1 cmKO shows cell area decreases compared to control
CMs. Student’s t test was used. P-value *<0.05
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Figure 5-3. Cell area measurements for PGC1/PPAR agonist related PSC-CM. Addition
of YAP1 inhibitor blunts the increase in cell size. Error bars represent SEM. P-value
*<0.05 **<0.01 ***<0.001. Control n= 35, PQQ n=36, PQQ+YAP Inh n=43, WY
n=59, WY+YAP n=40, PQQ+WY n=31, PQQ+WY+YAP Inh n=22
YAP1 is required for CM hypertrophy
To determine how PGC1/PPAR activation led to hypertrophy, we looked at the
expression trends of known regulators of cell size. Examining mTOR, YAP1, and
IGF1, we found that YAP1 was downregulated in PGC1 cmKO cells at P7. To
see if YAP1 affected cell size, we generated a YAP1 cmKO mouse and dissociated
cardiomyocytes. AAV9-cTnT-Cre was injected at P0 into YAP1 flox/flox and cells
were analyzed on P33. We saw a significant reduction in cell size in the postnatal YAP1
cmKO at P33 (Figure 5.2). Sandeep Kambhampati was responsible for analyzing the
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Figure 5-4. ChIP-qPCR shows enrichemnt of (a) PGC1α and (b) PPARα at the
promoters of YAP1 and SF3B2. ANOVA followed by post hoc Bonferroni tests were used.
*=p-value<0.05. n=6
images for cell size.
We next wanted to test whether YAP1 mediates the improvement in hypertro-
phy from PGC1/PPAR activation. To test this, we treated d15 hPSC-CMs with
PGC1α agonists and YAP1 inhibitor (R)-PFI-2 for 72 hours and found that YAP1
blocked the increase in cell size (Figure 5.3). This indicates that YAP1 is needed for
PGC1/PPAR activation to promote hypertrophy. This showed that YAP1 plays a
postnatal role in hypertrophy associated with CM maturation. Another study had
shown that PGC1α binds upstream of YAP1. We used chromatin immunoprecipitation
combined with custom designed qPCR primers targeting the upstream region of YAP1
and found it to be enriched (Figure 5.4). We validated this finding by looking at
the enrichment of known targets of PGC1/PPAR (Figure 5.5). This confirmed that
control sequences were not enriched while the promoter regions of known binding sites
were enriched.
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Figure 5-5. Antibodies were validated for (a) PPARα and (b) PGC1α known promoter
binding sites.
Figure 5-6. Experimental design to measure calcium transient kinetics in PPARα agonist
treated PSC-CMs
Functional siRNA screen identifies SF3B2
Our measurements of calcium transients in vivo cmKO showed decreased function.
We sought to determine how PGC1/PPAR regulate calcium handling. We used single
cell high-throughput calcium handling function measurements to see how WY14643
altered calcium transients after 11 days of treatment following differentiation (Figure
5.6). We found that agonist treated PSC-CMs have shorter calcium transient duration
(about 30ms shorter KS-D = 0.3114). The peak rise time was shortened from by about
10 ms showing faster intake of calcium and shorter calcium transient duration (Figure
5.7). This indicates that PGC1 and PPAR improve maturation through improving
PSC-CMs ability to perform calcium uptake and release associated with a sarcoplasmic
reticulum. These experiments were done in collaboration with Dr. Anais Kervadec
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Figure 5-7. a. Distribution of calcium transient duration (CTD) 75. b. Sample calcium
transient trace. c. median peak rise d. CTD50 shows a decrease in PPARα agonist
treated PSC-CMs d. CTD75 shows the same. Error bars represent standard deviation.
Student’s t-test was used. * p-value < 0.05. n= 3
Figure 5-8. Schematic for functional siRNA screen to determine PGC1/PPAR targets
regulating calcium handling. Student’s t-test was used. *=p-value<0.05. n=4
and Dr. Alexandre Colas.
To determine how a PPAR ligand improves calcium handling, we used a high
throughput screen of PSC-CM maturation. We had shown that 11-day teratment
of WY14643 improved maturation so we selected genes that were downregulated in
the single cell RNA-seq PGC1α cmKO dataset. We postulated that these genes are
activated by PGC1/PPAR in vivo in maturation since they were lower in expression
when PGC1 was knocked out. Therefore, we generated siRNAs targeting these 148
genes to see which would block the improvement in calcium handling. This would
indicate which gene(s) PGC1/PPARα activate in order to regulate to calcium han-
dling. PSC-CMs were differentiated and simultaneously treated with PPARα agonist
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Figure 5-9. siRNA screen functional readout of CTD-75 and Kolmogorov-Smirnov
Distance (KS-D). The positive control was PSC-CMs treated with a PPARα. Untreated
PSC-CMs were the negative control. n=1
WY14643 and the siRNAs for 11 days (Figure 5.8). Calcium transients were auto-
matically measured in a 386-well plate set and we selected all points that reduced
CTD75 time to that of our negative control (Figure 5.9). These were then validated by
repeating the experiment at n=4. The top 4 genes in terms of confidence were SF3B2,
SAP18, STRIP1, and TIMM50 (Figure 5.11). Representative calcium traces showing
dysregulation in both the initial screen and the validation are shown (Figure 5.12,5.14).
Using qPCR, we confirmed that the siRNAs, which were ordered from Dharmacon
horizon as a smartPOOL of different siRNAs, were able to knock down mRNA levels
(Figure 5.10). SF3B2 resulted in the largest change in CTD75 as it greatly elongated
PSC-CM calcium transient duration (Figure 5.13). SF3B2 and SAP18 are splicing
factors but have not been characterized in the heart. It is possible that these genes
splice key calcium handling genes including ion channels and sarcoplasmic reticulum
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Figure 5-10. siRNAs are able to knockdown expression of targets efficiently. n=2
proteins.
Discussion
These results identify a novel link between PGC1 and YAP1 in CM maturation. YAP1
may have dual roles and it has been proposed that this is a dose-based response in that
low levels of YAP activation result in hypertrophy and high levels lead to mitosis.123
Hippo/YAP have been linked to ERBB2 as drivers of CM re-entry into the cell cycle
and regeneration following ischemic injury. Our expression pattern of YAP supports
this idea because it is expressed at high levels in CMs with low maturation scores. We
also showed that the effect of PGC1/PPAR agonist on cell size and hypertrophy is
mediated by YAP as treatment with inhibitors prevents a significant increase in cell
size.
This study identified SF3B2 and SAP18 as novel targets of PGC1/PPARα (Figure
5.15). All four factors increased CTD75, indicating that calcium reuptake and
spontaneous beat rate were slower. Cardiac gene splicing has been investigated with
progress made in Titin splicing and isoform switching. However, splicing factors
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Figure 5-11. Median CTD75 shows validated screen hits significantly slow calcium
transient dynamics. Error bars represent standard deviation. ANOVA with post hoc
Bonferroni tests were used. P-value *<0.05 **<0.01 ***<0.001. n=4
as a critical regulator of maturation have not been studied. These splicing factors
may be required for splicing of calcium exchangers or other genes associated with the
sarcoplasmic reticulum. This suggests that PGC1/PPAR regulates maturation through
direct regulation of genes involved in calcium handling rather than a mitochondrial-
dependent mechanism where calcium transient shapes are improved by higher levels
of ATP in the cell. Additional work would be needed to confirm this hypothesis.
The screen and subsequent validation also discovered TIMM50 and STRIP1.
TIMM50 is a mitochondrial inner membrane translocase. Further investigation is
required, but it may show that PGC1 also acts through a mitochondrial-dependent
mechanism of promoting PSC-CM maturation. Striatin-interacting protein 1 (STRIP1)
is expressed at high levels in the embryo and is known to regulate cytoskeletal
organization. Overall, we have seen PGC1/PPAR improve PSC-CM maturation
through regulation of the expression of SF3B2 and YAP1 to improve calcium handling
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Figure 5-12. Contraction dynamics of control and siRNA treated PSC-CMs from the
validation experiments. These are representative traces.
Figure 5-13. Calcium transient quantification of siSF3B2 treated hiPSC-CMs. a. distri-
bution of individual cells CTD75. b. representative traces of calcium transient. c. Median
CTD75. d. Peak Rise time median. e. CTD90 median. f. Peak Decay Time median. Error
bars represent standard deviation. Student’s t-test was used. P-value *<0.05 **<0.01.
Control n=4, siSF3B2 n=3
and CM hypertrophy.
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Figure 5-14. Contraction dynamics of control and siRNA treated PSC-CMs from the
initial screen. These are representative traces.






microRNAs are small 22 nucleotide RNA molecules that bind to mRNAs and lead
to their degradation.132 MicroRNAs are present in all cell types and some have been
shown to be evolutionarily conserved. A single strand of RNA is transcribed and then
forms a loop called primary miRNA which is cleaved by Drosha or Pasha to form
the pre-miRNA. This loop is exported from the nucleus and cut by Dicer to form a
mature miRNA.133 These combine with an RNA-induced silencing complex (RISC) to
regulate genes post transcriptionally by silencing them.132 They do not have to be an
exact match so each miRNA can have hundreds of targets.
MicroRNAs play critical roles in the differentiation and maturation of skeletal
myocytes, erythrocytes, osteroclasts, neurons, retinal cells, cardiomyocytes, and
adipocytes.133–137 In a cardiac specific knockout of Dicer in the heart, mice develop di-
lated cardiomyopathy with postnatal lethality showing microRNAs are critical for heart
function.138 Treating fibroblasts with miR-1, miR-133, miR-208, and miR-499 were
able to facilitate cardiac reprogramming.139 Following microRNA-sequencing of day
20 PSC-CMs and 1 year old PSC-CMs, Let-7 was found to be highly upregulated.140
Overexpression of let-7 in PSC-CMs promotes maturation by downregulation of the
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PI3/AKT/Insulin pathway and increasing fatty acid oxidation.140 One drawback of
this is that 1 year cultured PSC-CMs are still immature compared to in vivo CMs.
This motivated our decision to use microRNA-seq to study in vivo maturation. Overex-
pressing miR-125b, miR-199a, miR-221, and miR-222, which target ERBB4 signaling,
was able to improve maturation that remained for 60 days after the transfection.141 An
integrated analysis of microRNA expression predicted miR-200c to be a blockade of
PSC-CM maturation. Overexpression of miR-200c lowered levels of Gata4, Tbx5, and
Srf. In addition, CACNA1C, a subunit of the L-type calcium channel was validated
as a direct target.142 These indicate that microRNAs play a crucial role in regulating
gene expression and have been shown to repress and promote CM maturation.143–145
Global organ maturation
The transcriptome can be used to describe a unique signature for an organ and track
the changes in gene expression over development. Organs change as they develop
and the gene regulatory network governing their morphogenesis and maturation has
not been described. With the goal of using RNA-seq to build profiles for use in
pharmacological testing, 11 organs across 4 timespoints (2, 6, 21, and 104 weeks after
birth) were collected in the rat in both male and female mice. They were able to
identify splicing variants and sex-specific isoform expression.146
In an investigation of human embryonic development, Xue et al. built a database
of gene expression from week 4 to week 9. However, they did not perform any analysis
and proposed that this dataset be used for studies of development and disease.147 In a
subsequent comparison of embryogenesis in human and mouse, Xue and colleagues
studied organogenesis similarities by looking for distinct temporal patterns of gene
regulation.148 Gene expression patterns were clustered by increases or decreases from
each stage, but they did not characterize the biological relevance of these patterns or
the genes in each cluster. They found that key genes in the Hedgehog, Notch, TGF-β,
82
and Wnt pathways were similarly regulated. These multiorgan datasets can be used
to identify markers of maturation that are consistent between humans and mice.8
Cardoso-Moreira et al. used bulk RNA-seq to track differences in the rate of
development across seven organs in multiple species including humans, rodents, rabbits,
chickens, and macaques.149 They found that the number of genes expressed decreases
and have similar stages of transcriptomic development. In a separate study of this
dataset, the dynamic expression of long noncoding RNAs (lncRNAs) was characterized.
They found that there some lncRNAs are expressed across multiple lineages early
on, but more organ-specific lncRNAs were predominantly expressed later on.150 The
Tabula Muris Consortium sought to build a transcriptomic single cell atlas. Previously
they sequenced more than 100,000 cells from 20 different tissues in adult mice.88 Most
recently, they published a dataset of 350,000 cells from both male and female mice
from 1 month to 30 months for analysis of aging. While this is a magnificent resource,
neither focus on the key developmental window where cardimyocytes mature.87 Most of
these have been created as a resource rather than providing insight into the mechanism
of maturation.
We are interested in identifying similarities in maturation across organs in both
microRNA and mRNA expression. Using a microRNA-seq dataset of maturation in the
brain, heart, and liver, we identify key microRNAs that are consistently upregulated
in multiple organs. Using co-expression trends, we predict top regulators of global
maturation from a meta-analysis of microarray datasets.
Materials and Methods
Data gathering
Affymetrix Mouse 430 2.0 microarray dataset were compiled from the National Center
for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO). Bioconduc-
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tor in R was used to curate datasets from liver, heart, kidney, and brain. Datasets were
selected to cover the major developmental stages from embryonic to adult. Datasets
included 479 brain, 147 liver, 142 kidney, and 212 heart samples. All samples were wild-
type non-treated conditions and were grouped into early embryonic, mid embryonic,
late embryonic, neonatal, adolescent, and adult. Frozen robust multi-array average
(fRMA) was used to normalize datasets.151 Probe-sets with the largest dynamic range
were selected to convert a probesets to gene official symbol.
Differential expression analysis
Differentially expressed genes were identified using limma in each specific organ.152
Limma was used because it commonly used in microarray differential expression
analysis whereas DESeq2 is designed for RNA-seq. We used a cutoff of p-value less
than 0.01 and log fold change greater than 2.
Clustering
Principal component analysis (PCA) was used on the full probeset of expression data
with the prcomp function in R. Gene expression data was collected by using probes
with the largest interquartile range of expression. The mFuzz R package was used for
fuzzy clustering.112 We selected the number of clusters by iteratively increasing the
clusters until the correlation between two clusters was greater than 0.85. The core
genes with a membership greater than 0.5 were selected for further analysis.
Gene Regulatory Network Prediction
Weighted Gene CO-Expression Network Analysis (WGCNA) was used to group
genes into modules by similarities in their expression patterns across samples.97 The
correlation network is a collection of pairwise correlations between genes that range
from -1 to 1. Hub genes are centrally located in the group. Correlation networks were
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made for each organ with a signed network using biweight midcorrelation, a maximum
block size of 21000 and a soft thresholding power of 12. The developmental stages
were set as an external trait so that each module could be correlated with time over
maturation. The correlation with development and the p-value were used to select the
most relevant modules. Genes were selected by taking the top 3000 based on module
membership values or the top 300 genes based on intramodular connectivity scores.
The consensus maturation network was made by using data from all organs. Ingenuity
pathway analysis (IPA) was used to generate a list of predicted upstream regulators
of maturation.
microRNA sequencing and analysis
Organs were harvested from E18.5, P0, P7, P14, and P28 mice. Tissues were cleaned
in PBS the frozen at -80 C. RNA was isolated by adding 600 uL of TRIzol (Thermo
Fisher Scientific). Tissue samples were homogenized then using Direct-Zol RNA
isolation kit (Zymo Research). The Illumina TruSeq Small RNA Library Preparation
kit with indexes 1-24 were used to prepare libraries for sequencing on a NextSeq 500
lane. FASTQ files were aligned with bowtie2 then aligned with featurecounts to the
mouse genome.92 The sRNAtoolbox was used to select hairpin and mature miRNA
sequences present.153 Differential expression analysis was completed with DESeq2 then
visualized with ggplot2.93
Results
Cross organ maturation comparison
Since maturation has been shown to occur in multiple organs, we sought to investigate
the similarities in development of the heart, liver, kidney, and brain. We compiled
a meta-analysis of microarray data spanning early embryonic to adult timepoints
from 980 samples. The expression was normalized using fRMA then visualized using
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Figure 6-1. a. 3D PCA plot of multiorgan gene expression. b. PC2 and PC3 showing
organ maturation with clustering at early stages.
principal component analysis (Figure 6.1). We see that the temporal pattern is
captured by PC2 and PC3. PC1 primarily separates samples based on organ specific
aspects of maturation. This shows that many of the early timepoints cluster closely
together then diverge. However, they progress in the same direction. This indicates
that there may be transcriptomic similarities. Our goal became to determine what
common pathways are activated or repressed across multi-organ maturation. Individual
PCA clustering of organ data (Figure 6.2) resulted in a clear clustering by timepoint
and trajectory present in PC1. This indicates that there is a directional change in
gene expression in all organs after formation that continues to occur postnatally.
To determine which genes were changing over the developmental trajectory, we
used fuzzy clustering of expression. This normalizes each expression trend to a shape
then groups genes based on that trend. This work was done in collaboration with
Sandeep Kambhampati. Timepoints like E18.5 were binned by developmental stage
such as late embryonic. We ran fuzzy clustering over the binned timepoints to generate
clusters by increasing the number until cluster correlation was 0.85. The clusters with
downregulation of genes were visually selected. There were two clusters per organ
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Figure 6-2. PCA plots showing time series trajectory for maturation of each organ.
where the core cluster genes continued to decrease in expression for each group (Figure
6.3). The genes in the decreasing expression clusters were selected for each organ and
input into GO analysis to determine enriched GO terms through gene set enrichment
analysis with a cut-off p-value of 0.05. From the 4 lists of GO terms, selected terms
that were present in at least two of the lists were presented with their p-value and
normalized enrichment score (NES) (Figure 6.4). The kidney and the heart have the
most overlap in GO terms with the brain also showing enrichment for terms related
to cell cycle. It appears that downregulation of cell cycle and mitotic genes are the
most common terms present. This is expected as growth slows because the organ
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Figure 6-3. Downregulated gene clusters from fuzzy clustering for each organ.
reaches a steady state size. Cell cycle exit is a hallmark of maturation in multiple
organs. The liver does not show enrichment for these terms. This could be caused by
the regenerative nature of hepatocytes and epithelial cells of the bile duct. However,
the liver overlap GO terms showed DNA conformational change, which could indicate
that there is an alteration of chromatin structure in maturation, but continues in the
cell cycle.
We then selected the upregulated gene expression patterns from the fuzzy clustering
for each organ (Figure 6.5). GO analysis was run then a comparison of shared GO terms
was compiled (Figure 6.6). There is a clear overlap in metabolic and mitochondrial-
related GO terms such as fatty acid β oxidation and electron transport chain between
the heart, liver, and kidney. The brain shows similar upregulation of genes involved
in NFkB signaling along with calcium transport. The presence indicates an increased
energy demand of the organs in adulthood compared to the embryonic and neonatal
stages. The brain and kidney showed a strong enrichment of circadian rhythm genes.
We next sought to characterize the gene regulatory networks of the developing
organs. First, the microarray dataset was used to generate a weighted co-expression
matrix (Figure 6.7). Hierarchical clustering was then used to group co-expressed
genes into modules. The eigenvalue of each module was calculated in relation to the
developmental stage. This identified modules whose expression pattern was correlated
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Figure 6-4. Top GO terms present in at least 2 individual organ GO term sets from fuzzy
clustering downregulated clusters.
with time. We selected the top gene network modules positively and negatively
associated with maturation for each organ. Genes that were present in multiple
modules were selected and listed as hub genes.
After determining that cell cycle genes are commonly downregulated and the
metabolic genes are upregulated, we wanted to identify upstream regulators. To
predict the upstream regulators of maturation processes, IPA was used to evaluate
the differentiatially expressed genes between stages and assess the activation state of
regulators. The negatively enriched regulators which become more negative over time
include cell cycle activators such as cyclin CCND1 and E2F family members such as
E2F2, E2F3, TFDP1, and E2F1 (Figure 6.8). Other upstream regulators included
MYC, IGF2BP1, and FOXM1. The same process was used to select the positive
z-scored upstream regulators (Figure 6.9). As expected, multiple transcriptional
regulators were related to mitochondrial and metabolic functions including PGC1α,
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Figure 6-5. Upregulated gene clusters from fuzzy clustering for each organ.
PGC1β, PPARγ, and PPARα. This analysis also yielded cell cycle repressors including
E2F6, TP53, and CDKN2A. Epigenetic regulators HDAC1 and HDAC2 are predicted
to be positively activated during maturation across the heart, liver, brain, and kidney.
Future studies could knock out these genes to see if maturation defects occur across
multiple tissues.
microRNA across multiple organs in maturation
microRNAs have been shown to be very important in differentiation and maturation
across multiple tissues. A cocktail of microRNAs is sufficient to induce cardiac cell fate
reprogramming in fibroblasts. MicroRNA expression trends across multiple organs
has not been investigated and may play a common role in post transcriptional gene
regulation. To track miRNA expression, we used small RNA sequencing selected from
the brain, liver, and heart at 5 timepoints from E13.5 to P28 in the mouse (Figure
6.10). We were able to map to both mature microRNA and primary microRNA
(Figure 6.11). PCA clustering of each organ showed a temporal trend present in PC1.
This indicates that microRNA patterns change with time showing that not only a few
are differentially regulated. This may include gradual changes in microRNA or stage
specific microRNA expression. We then plotted the PCA of all organs combined and
found that they cluster by organ type rather than timepoint (Figure 6.12). This is a
strong indication that the majority of microRNA expression is organ specific. Using a
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Figure 6-6. Top GO terms present in at least 2 individual organ GO term sets from fuzzy
clustering upregulated clusters.
heatmap of normalized expression with hierarchical clustering of points, we see that
the brain separates out while the liver and heart points are interspersed. Therefore
the heart and liver may be more similar than the other pairings (Figure 6.13).
To identify the conserved microRNAs that are independent of organ type, differen-
tial expression was used to select microRNAs with a 2 fold change either up or down.
The heart had 64 upregulated and 118 downregulated as brain had 112 up and 156
down and the liver had 64 up with 86 down. 11 microRNAs were conserved across the
upregulated datasets and 13 from the downregulated miRNAs (Figure 6.14). Let-7
was found to be conserved in our upregulated dataset and has been shown to improve
cardiac maturation when overexpressed.140 miR-6538 is a downregulated microRNA
across multiple organs(Figure 6.15). It may suppress mRNAs encoding maturation
genes. In addition, miR-29c is an example of one that was consistently upregulated
in all three organs to different extents. It may degrade transcripts that promote cell
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Figure 6-7. WGCNA modules positively and negatively correlated with maturation.
Separate GRNs were constructed for each organ.
92
Figure 6-8. Heatmap showing the IPA activation scores of predicted upstream regulators
between stages. This summarizes the top positively enriched transcriptional regulators.
cycle or immature processes.
Discussion
In a massive meta-analysis of publicly available microarray datasets, we developed a
map of transcriptomic maturation for the heart, brain, liver, and kidney. We showed
that organs progress in their gene expression changes. The maturation transition
results in a traceable progression that forms a trajectory in PCA. Since PCA is a
linear transformation, the distance between points on the plot is representative of the
difference in gene expression. The combined PCA plot showing all organs indicates that
they start close together then begin expressing organ specific genes. It is remarkable
that they separate, but progress in the same direction. Using fuzzy clustering of gene
trends and then interpreting those with GO terms, we discovered that cell cycle genes
are commonly downregulated and metabolic genes are upregulated. This is expected
since organs reach a steady-state size and cell turnover is reduced to maintaining that
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Figure 6-9. Heatmap showing the IPA activation scores of predicted upstream regulators
between stages. This summarizes the top negatively enriched transcriptional regulators.
size. The rate of cell cycle differs as cardiomyocytes and neurons are not regenerative,
while the liver is regenerative.
Differentially expressed genes that are up and downregulated for each organ were
put into IPA to predict upstream regulations. We presented the activation score for top
regulators. These matched our GO terms as metabolic and mitochondrial regulators
were highly activated in maturation and cell cycle regulators were inactivated. This
work was primarily descriptive as it looked for trends and specific genes and miRNAs
in maturation that could be important. While we did not find a single pathway that
controls all of maturation, we did construct a list of potential regulators that could be
tested experimentally in the future.
In the analysis of microRNA trends, we were able to find microRNAs that have
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Figure 6-10. Experimental design of microRNA-seq. microRNA was collected from the
brain, heart and liver then sequenced.
Figure 6-11. Timeline of organ collection for microRNA plots
similar trends. Since microRNAs alone have the ability to reprogram cells, it is possible
that they have the ability to regulate maturation.139 The next step for this work
would be to compare the known and predicted targets of each of the top microRNAs.
That may provide insight into which genes are suppressed during maturation. This
could be combined with the transcriptomic data looking for maturation. Next, we
plan on using qPCR to assess the expression levels of each microRNA in PSC-CMs to
select dysregulated microRNAs for overexpression. These may promote maturation
in PSC-CMs in vitro. In addition, we could run loss of function studies to examine
the role they play in vivo. Suppressing miR expression can be challenging because
regulation of microRNAs can be located in introns. Therefore antisense microRNAs
and CRISPR/Cas9 methods have arisen as possible tools.154,155
After this project was completed, RNA-seq datasets became more prevalent. RNA-
seq does not require probesets so it can measure the entire transcriptome revealing
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Figure 6-12. Temporal maturation is captured in all individual organ PCA plots. PCA of
all combined data shows organ-specific clustering
isoform differences with scalable depth rather than predefined targets. A downside
of bulk RNA-seq is that it does not differentiate between cells so it combines many
different cell types. At this time, there are single cell atlases of multiple organs, but not
time series datasets. Another area of interest has been similarities in different species
and the rate of maturation. Mice reach adolescence after 4 weeks, while humans take
more than 10 years. It has been shown that CM maturation follows a similar time
course.
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Figure 6-13. Heatmap of top microRNA expression shows organ specific signatures.
Figure 6-14. Overlap between microRNAs shows 11 conserved upregulated and 13
conserved downregulated microRNAs, which are listed.
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The goal of these experiments was to unveil part of the mechanism of cardiomyocyte
maturation. By learning more about the gene regulatory network driving CM matura-
tion, we can alter pathways to generate mature PSC-CMs in the dish. In chapter 1, I
laid out the current knowledge of the field and described previous efforts to improve
maturation of PSC-CMs. These centered around biomimetic approaches to recreate
aspects of the in vivo microenvironment including ECM, mechanical stretching, and
electrical stimulation. In chapter 2, I used a meta-analysis of bulk RNA-seq sets to
characterize expression trends and predict upstream regulators. We confirmed and
identified a novel characteristic of transcriptomic maturation which was the critical
window. There appears to be a large shift in gene expression between P7 and P14. We
then found that PGC1α was a key predicted upstream regulator and was misregulated
in PSC-CMs. Single cell RNA-seq of postnatal maturation supported this conclusion
as fatty acid oxidation pathways were consistently activated. In chapter 3, we sought
to determine if PGC1α was required for postnatal cardiomyocyte maturation in vivo.
We used a conditional mosaic knockout to assess the cell autonomous role using a
Cre-lox system with AAV9. After 4 weeks, we measured CM contractility and calcium
transients showing that their dynamics resembled immature CMs. The PGC1 null
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cells were smaller than control CMs through development and scRNA-seq found that
they were consistently less mature.
In chapter 4, we found that these findings could be applied to PSC-CMs. Impor-
tantly, PGC1α and PPARα activation following differentiation led to more forceful
contraction and hypertrophic growth. These PSC-CMs had nearly 3-fold higher
mitochondrial density and significantly higher mitochondrial respiratory capacity.
Since PGC1/PPAR are regulators of metabolism and mitochondrial biogenesis, we
were interested in how they altered calcium handling, hypertrophy, and contractility
and studied this in chapter 5. Using a functional siRNA screen of potential PGC1
targets from the scRNA-seq analysis, we found that SF3B2 was a splicing factor that
was required for improvement of calcium handling. SF3B2 has not been studied in
the heart and may splice mRNA for proteins involved in the sarcoplasmic reticu-
lum. We also found that YAP1 is required for both postnatal CM hypertrophy and
PGC1/PPAR-mediated cell growth.
In chapter 6, we investigated similarities in maturation across multiple organs.
Looking into mRNA and microRNA expression, we were able to identify key pathways
and potential microRNAs that could promote PSC-CM maturation. These findings
could be applied to improving maturation of stem cell derived-hepatocytes, neurons,
and other cell types.
Conclusions
We searched for a key regulator of CM maturation. PGC1 was found to control multiple
aspects of maturation including hypertrophy, contractility, and gene expression. While
our PSC-CMs did not become adult-like in the dish, they did exhibit improved
functional parameters, which may make PSC-CMs more useful in disease modeling.
Further studies are required to see if PGC1 can be combined with 3D culture and other
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small molecule regulators to generate the most mature PSC-CMs developed in vitro.
However, this would require a better method of comparing matured PSC-CMs between
labs. It has been difficult to compare the maturation state of cells as many aspects
of maturation must be measured. We did not characterize T-tubule development,
multinucleation, elongation, or proliferation, which may have been affected by PGC1
agonist treatment.
Our development of a Cre-lox system for preparation of conditional mosaic knock-
outs could be impactful as floxed mouse lines exist for many genes. We recommend
that other studies of maturation use a cell autonomous approach to rule out feedback
loops from altering cellular function. Our siRNA screen of PGC1 targets on calcium
handling identified multiple splicing factors. One drawback of this work is that it did
not look into the alternative splicing caused by siSF2B2.
Future directions
Our results showed scRNA-seq analysis can identify transcriptional regulators of CM
maturation. Multiple other factors were predicted to be upstream regulators of CM
maturation. We plan on interrogating these factors in a similar manner. However, we
will need to first confirm that they are misregulated in PSC-CMs. Since the qPCR
analysis of expression was labor intensive, it will be better to use a time series RNA-seq
dataset of PSC-CM maturation to determine the expression trends. One drawback
is that signaling pathways could be activated or suppressed by post-translational
modifications that do not change mRNA levels.
The first drawback of our study is that PSC-CMs matured, but were still unlike
in vivo CMs. With the goal of generating adult-like PSC-CMs, the best approach
may be to combine pathway modifications like our PGC1/PPAR agonists with 3D
culture systems like an engineered heart tissue. In addition, our PGC1/PPAR agonist
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treated-PSC-CMs were cultured in normal media containing high levels of glucose
and low levels of fatty acids. Since glucose was shown to inhibit CM maturation, it is
possible that these factors are limiting the impact of PGC1/PPAR agonists. Other
studies have shown that PGC1 expression is upregulated by culture on microgrooved
surfaces. We are interested in determining what upregulates PGC1α in vivo and
whether that cue can be added to PSC-CM culture.
The PGC1α activator PQQ is not a specific agonist. It acts by increasing the
phosphorylation of CREB at serine 133, which activates PQQ. We did validate some
of our results using a PGC1α overexpression plasmid in PSC-CMs, but it would be
interesting to see how a physiologically-relevant overexpression could alter maturation.
SF3B2 was shown to be required for calcium handling. This factor has not been
studied in cardiomyocytes. We plan on performing loss of function studies using a
similar conditional knockout of SF3B2 using a Cre-Lox with an αMHC-Cre. Since
these mice do not exist, we will need to generate a floxed SF3B2 mouse line. If a
phenotype develops, we will perform postnatal conditional mosaic knockouts of the
factor to determine the cell autonomous effects. Our lab has been creating a PSC-CM
line expressing dCas9-KRAB to repress gene expression when single guide RNAs
are transfected. We can use this system to see if SF3B2 is required for PSC-CM
function. Since SF3B2 is a splicing factor, we are interested in finding the mRNAs
that are spliced by SF3B2. Using cross linking immunoprecipitation sequencing, we
could determine the mRNAs that are bound by SF3B2. Deep sequencing of the
transcriptome could also determine alternative splicing by SF3B2 in our knockout
mice. Our initial results indicate that SF3B2 plays a critical role in calcium handling
so it will be interesting to elucidate this mechanism.
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Table I-I. ChIP-qPCR oligonucleotdes
Primer Name Sequence
ESRRA promoter qF ACTGAACAGCTACGCCCACT
KLB promoter qF GAGAAAACGCCATTCTCAGG
PSD4 promoter qF AGCCAGCTGTGTGGAGAGTT
PGC1a promoter qF CAAGCTGAGTCTGGGGCTAC
PPARA promoter qF CAGCAGCCAATCAGACACTG
TAZ promoter qF TTTCCACCAGCCTACGACTT
ESRRA promoter qR CAGGCCTTGTCGATACACAC
KLB promoter qR TAGGATGGGGTCATGAGAGC
PSD4 promoter qR GACGTCAGCCAGCTACAGGT
PGC1a promoter qR TGTGACTGAAGCCAGCTTTG
PPARA promoter qR CTGTCGTGGGACCGTAGC
TAZ promoter qR GTTGTCGCAAAACATGCCTA
CSMD1 promoter qF AACAAGTCTCCGTGCTCCAG
ZFPM2 promoter qF TGGAAGAAGTTGCTGGAAGG
LRBA promoter qF CGTTCTGTGGCAGTAGCATC
ASIC2 promoter qF AAGAAGGGTCCTGGAGGAAA
TMEM178B promoter qF GAGAAGAGGGCAGCAGAATG
ACOX1 promoter qF AACGACAATGAACCGTCTCC
SULT2A1 promoter qF TCCATGGAAAGGTTCTGTATGA
ACADL promoter qF AAACAACCATATGCGAGTTCAA
CD36 promoter qF TGGGCCATTTCCTTTTGTAA
CSMD1 promoter qR TGGACTCAACCATCCTACCC
ZFPM2 promoter qR ACTATGCCATCAGCGAAAGG
LRBA promoter qR GAGAAAGGTCAAGGCACCTG
ASIC2 promoter qR CCACTAGTCTGGCCCTTAGC
TMEM178B promoter qR TTTGCTCCCTTGGTGATAGC
ACOX1 promoter qR GTGGGACTCACCTCCTTTCA
SULT2A1 promoter qR CCAAGTTCATGACCCCAAAT
ACADL promoter qR TGCTGATTTGGTTTGGGTTT
CD36 promoter qR GTCCCAACAAAGCCTGAAAA
GAPDH promoter qF TCCGCAGCCTTTTCAATAAT
HPCAL1 promoter qF CTGGCCATTGGGACTGTACT
GAPDH promoter qR GAGGAGTCCTTGGAGTGTGC
HPCAL1 promoter qR GATGGGTGTTAAGGCCACTG
ESRRA intron qF TCCAGGACGGACAGAAAAAG
SP7 intron qF CCCCTTCCTCTCCCTCTATG
ESRRA intron qR AGAAATCCGCCTGCCTCT
SP7 intron qR CTGCCAGAGGTCCTGAGTTC
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Table I-II. Knockout validation primers
Primer Name Sequence
PGC1a exon 2-7 qF TCGGAAATCATATCCAACCAG
PGC1a exon 2-7 qR TGCAGTTCCAGAGAGTTCCA
PGC1a exon 2-3 qF AACAATGAGCCTGCGAACAT
PGC1a exon 2-3 qR ACTGGCCTCGTTGTCAGTG
PGCb exon 3-4 qF GGACGCCAGTGACTTTGACT
PGCb exon 3-4 qR TTCATCCAGTTCTGGGAAGG
PGCb exon 3-8 qF ACAGCTGTGTGCTGACTTGC
PGCb exon 3-8 qR CCAAGAGAGTCGCTTTGTGA
PGCb exon 3-9 qF GGACGCCAGTGACTTTGACT
PGCb exon 3-9 qR GGCTTGTATGGAGGTGTGGT
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Table I-III. PGC1 cmKO differentially expressed genes
GO Term P-value FDR
GO:0051179 localization 1.44E-12 0.00%
GO:0055114 oxidation-reduction process 1.53E-12 0.00%
GO:0046034 ATP metabolic process 3.10E-12 0.00%
GO:0060048 cardiac muscle contraction 5.50E-12 0.00%
GO:0008152 metabolic process 1.33E-11 0.00%
GO:0051234 establishment of localization 1.59E-11 0.00%
GO:0009205 purine ribonucleoside triphosphate metabolic process 2.09E-11 0.00%
GO:0009199 ribonucleoside triphosphate metabolic process 2.82E-11 0.00%
GO:0009167 purine ribonucleoside monophosphate metabolic process 4.17E-11 0.00%
GO:0009126 purine nucleoside monophosphate metabolic process 4.59E-11 0.00%
GO:0009144 purine nucleoside triphosphate metabolic process 4.59E-11 0.00%
GO:0006941 striated muscle contraction 4.76E-11 0.00%
GO:0009161 ribonucleoside monophosphate metabolic process 5.56E-11 0.00%
GO:0006810 transport 6.26E-11 0.00%
GO:0044237 cellular metabolic process 8.32E-11 0.00%
GO:0009123 nucleoside monophosphate metabolic process 1.18E-10 0.00%
GO:0045333 cellular respiration 1.53E-10 0.00%
GO:0009141 nucleoside triphosphate metabolic process 2.64E-10 0.00%
GO:0055008 cardiac muscle tissue morphogenesis 5.93E-10 0.00%
GO:0022900 electron transport chain 1.34E-09 0.00%
GO:0060047 heart contraction 1.36E-09 0.00%
GO:0003015 heart process 1.83E-09 0.00%
GO:0044699 single-organism process 2.81E-09 0.00%
GO:0046128 purine ribonucleoside metabolic process 2.83E-09 0.00%
GO:0042278 purine nucleoside metabolic process 3.84E-09 0.00%
GO:0060415 muscle tissue morphogenesis 5.88E-09 0.00%
GO:0006091 generation of precursor metabolites and energy 6.49E-09 0.00%
GO:0006807 nitrogen compound metabolic process 9.95E-09 0.00%
GO:0006936 muscle contraction 1.02E-08 0.00%
GO:0003012 muscle system process 1.02E-08 0.00%
GO:0009119 ribonucleoside metabolic process 1.07E-08 0.00%
GO:0022904 respiratory electron transport chain 1.17E-08 0.00%
Continued on next page
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GO Term P-value FDR
GO:0034641 cellular nitrogen compound metabolic process 1.25E-08 0.00%
GO:1901657 glycosyl compound metabolic process 1.55E-08 0.00%
GO:0048644 muscle organ morphogenesis 2.20E-08 0.00%
GO:0016043 cellular component organization 2.70E-08 0.00%
GO:0009116 nucleoside metabolic process 3.20E-08 0.00%
GO:0007507 heart development 3.63E-08 0.00%
GO:0003007 heart morphogenesis 3.65E-08 0.00%
GO:0048738 cardiac muscle tissue development 3.76E-08 0.00%
GO:0006725 cellular aromatic compound metabolic process 5.42E-08 0.00%
GO:0006139 nucleobase-containing compound metabolic process 5.87E-08 0.00%
GO:0046483 heterocycle metabolic process 5.98E-08 0.00%
GO:0071704 organic substance metabolic process 1.46E-07 0.00%
GO:0044238 primary metabolic process 1.46E-07 0.00%
GO:0071840 cellular component organization or biogenesis 1.88E-07 0.00%
GO:1901360 organic cyclic compound metabolic process 2.33E-07 0.00%
GO:0043933 macromolecular complex subunit organization 5.13E-07 0.00%
GO:0015980 energy derivation by oxidation of organic compounds 5.37E-07 0.00%
GO:0009987 cellular process 5.53E-07 0.00%
GO:0044763 single-organism cellular process 7.93E-07 0.00%
GO:0042775 mitochondrial ATP synthesis coupled electron transport 8.34E-07 0.00%
GO:0009150 purine ribonucleotide metabolic process 1.09E-06 0.00%
GO:0048523 negative regulation of cellular process 1.19E-06 0.00%
GO:0009259 ribonucleotide metabolic process 1.60E-06 0.00%
GO:0042773 ATP synthesis coupled electron transport 1.97E-06 0.00%
GO:0006163 purine nucleotide metabolic process 2.02E-06 0.00%
GO:0048519 negative regulation of biological process 2.04E-06 0.00%
GO:0009117 nucleotide metabolic process 2.16E-06 0.00%
GO:0019693 ribose phosphate metabolic process 2.78E-06 0.00%
GO:0055010 ventricular cardiac muscle tissue morphogenesis 2.93E-06 0.00%
GO:0072521 purine-containing compound metabolic process 3.08E-06 0.00%
GO:0006753 nucleoside phosphate metabolic process 3.34E-06 0.00%
GO:0060537 muscle tissue development 3.48E-06 0.00%
GO:0003205 cardiac chamber development 5.35E-06 0.00%
Continued on next page
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GO Term P-value FDR
GO:0008015 blood circulation 5.77E-06 0.00%
GO:0014706 striated muscle tissue development 6.87E-06 0.00%
GO:0003013 circulatory system process 6.91E-06 0.00%
GO:0030239 myofibril assembly 7.41E-06 0.00%
GO:1902589 single-organism organelle organization 8.36E-06 0.00%
GO:0003229 ventricular cardiac muscle tissue development 1.05E-05 0.00%
GO:0003231 cardiac ventricle development 1.07E-05 0.00%
GO:0003208 cardiac ventricle morphogenesis 1.27E-05 0.00%
GO:0044710 single-organism metabolic process 1.82E-05 0.00%
GO:0055086 nucleobase-containing small molecule metabolic process 1.98E-05 0.00%
GO:0019637 organophosphate metabolic process 2.07E-05 0.00%
GO:0015985 energy coupled proton transport, down electrochemical gradient 3.54E-05 0.00%
GO:0015986 ATP synthesis coupled proton transport 3.54E-05 0.00%
GO:0015992 proton transport 4.58E-05 0.00%
GO:0006818 hydrogen transport 5.16E-05 0.00%
GO:0007517 muscle organ development 5.90E-05 0.00%
GO:1902600 hydrogen ion transmembrane transport 6.26E-05 0.00%
GO:0006119 oxidative phosphorylation 6.50E-05 0.00%
GO:0006996 organelle organization 7.08E-05 0.00%
GO:0072359 circulatory system development 8.69E-05 0.00%
GO:0061061 muscle structure development 0.0001197 0.00%
GO:0022607 cellular component assembly 0.0001423 0.00%
GO:1901576 organic substance biosynthetic process 0.00019825 0.00%
GO:0051171 regulation of nitrogen compound metabolic process 0.00020217 0.00%
GO:0008016 regulation of heart contraction 0.00020908 0.00%
GO:0009058 biosynthetic process 0.00023073 0.00%
GO:0044057 regulation of system process 0.000274 0.00%
GO:0044249 cellular biosynthetic process 0.00027699 0.00%
GO:0065008 regulation of biological quality 0.00037452 0.00%
GO:0006754 ATP biosynthetic process 0.00037544 0.00%
GO:0009127 purine nucleoside monophosphate biosynthetic process 0.00049528 0.00%
GO:0009168 purine ribonucleoside monophosphate biosynthetic process 0.00049528 0.00%
GO:0010468 regulation of gene expression 0.00052977 0.00%
Continued on next page
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GO:0006123 mitochondrial electron transport, cytochrome c to oxygen 0.00056503 0.00%
GO:0003206 cardiac chamber morphogenesis 0.00059131 0.00%
GO:0006793 phosphorus metabolic process 0.00063471 0.00%
GO:0009156 ribonucleoside monophosphate biosynthetic process 0.00072357 0.00%
GO:0065003 macromolecular complex assembly 0.0007811 0.00%
GO:0009142 nucleoside triphosphate biosynthetic process 0.00092218 0.00%
GO:0010927 cellular component assembly involved in morphogenesis 0.0010402 0.00%
GO:0044281 small molecule metabolic process 0.00117409 0.00%
GO:1901564 organonitrogen compound metabolic process 0.00121963 0.00%
GO:0019219 regulation of nucleobase-containing compound metabolic process 0.0012365 0.00%
GO:0044085 cellular component biogenesis 0.00128161 0.00%
GO:0006796 phosphate-containing compound metabolic process 0.00128443 0.00%
GO:0009124 nucleoside monophosphate biosynthetic process 0.00130824 0.00%
GO:0009206 purine ribonucleoside triphosphate biosynthetic process 0.00195086 0.00%
GO:0009145 purine nucleoside triphosphate biosynthetic process 0.00222598 0.00%
GO:0009201 ribonucleoside triphosphate biosynthetic process 0.0025335 0.00%
GO:0009653 anatomical structure morphogenesis 0.00265502 0.00%
GO:0055002 striated muscle cell development 0.00306339 0.00%
GO:0043462 regulation of ATPase activity 0.00314238 0.00%
GO:0010467 gene expression 0.00323753 0.00%
GO:0009060 aerobic respiration 0.0032583 0.00%
GO:0098662 inorganic cation transmembrane transport 0.00346989 0.00%
GO:0051239 regulation of multicellular organismal process 0.00365692 0.00%
GO:0010605 negative regulation of macromolecule metabolic process 0.00405621 0.00%
GO:0042451 purine nucleoside biosynthetic process 0.00416063 0.00%
GO:0046129 purine ribonucleoside biosynthetic process 0.00416063 0.00%
GO:0031032 actomyosin structure organization 0.00421994 0.00%
GO:2000112 regulation of cellular macromolecule biosynthetic process 0.00424466 0.00%
GO:0060255 regulation of macromolecule metabolic process 0.00463497 0.00%
GO:0009892 negative regulation of metabolic process 0.00604075 0.02%
GO:0030048 actin filament-based movement 0.00607754 0.02%
GO:0030029 actin filament-based process 0.00633614 0.02%
GO:1903522 regulation of blood circulation 0.00641667 0.02%
Continued on next page
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GO:0048729 tissue morphogenesis 0.0065094 0.02%
GO:0080090 regulation of primary metabolic process 0.00652219 0.02%
GO:0070252 actin-mediated cell contraction 0.00657864 0.03%
GO:0010629 negative regulation of gene expression 0.00763574 0.03%
GO:0055001 muscle cell development 0.00869612 0.03%
GO:0034654 nucleobase-containing compound biosynthetic process 0.0087891 0.03%
GO:0051641 cellular localization 0.00906754 0.03%
GO:0031323 regulation of cellular metabolic process 0.00962081 0.03%
GO:0019438 aromatic compound biosynthetic process 0.00964853 0.03%






for file in *.fastq
do
java -jar trimmomatic-0.36.jar SE -phred33 ~/Documents/HISAT2_HOME/"$file"
~/Documents/HISAT2_HOME/"t2$file" ILLUMINACLIP:NexteraPE-PE.fa:2:30:10
LEADING:38 TRAILING:35 SLIDINGWINDOW:4:20 MINLEN:36
done
for file2 in ps*.fastq
do




./featureCounts -t exon -g gene_id -a refFlat.gtf -o counts.txt ~/Documents/
HISAT2_HOME/ps*.sam
B. R script
library(Seurat) #this uses Seurat v2.4
#barcodes for cells
wt_cells <- pbmc@cell.names[pbmc@meta.data$rfp == "RFP-"]
#timepoints
tps <- pbmc@meta.data$timepoint[pbmc@meta.data$rfp == "RFP-"]
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#greate a new seurat object that is a subset of pbmc input
wild_type_cells <- CreateSeuratObject(raw.data = data[,wt_cells])
wild_type_cells <- NormalizeData(object = wild_type_cells, normalization.method =
"LogNormalize",
scale.factor = 10000)
mito.genes <- grep(pattern = "^MT-", x = rownames(x = pbmc@data), value = TRUE)
percent.mito <- Matrix::colSums(pbmc@raw.data[mito.genes, ])/Matrix::colSums(wild_
type_cells@raw.data)
wild_type_cells <- AddMetaData(object = wild_type_cells, metadata = percent.mito,
col.name = "percent.mito")
wild_type_cells <- AddMetaData(object = wild_type_cells, metadata = tps, col.name
= "timepoint")
wild_type_cells <- ScaleData(object = wild_type_cells, vars.to.regress = c("nUMI",
"percent.mito"))
wild_type_cells <- FindVariableGenes(object = wild_type_cells, mean.function =
ExpMean, dispersion.function = LogVMR,
x.low.cutoff = 0.0125, x.high.cutoff = 3, y.cutoff = 0.5)
wild_type_cells <- RunPCA(object = wild_type_cells, pc.genes = wild_type_cells@var.
genes, do.print = TRUE, pcs.print = 1:5,
genes.print = 5)
wild_type_cells <- RunTSNE(object = wild_type_cells, dims.use = 1:10, do.fast =
TRUE)
TSNEPlot(object = wild_type_cells, pt.size = 2)
wild_type_cells <- RunUMAP(object = wild_type_cells, dims.use = 1:10, do.fast =
TRUE)
UMAPPlot(object = wild_type_cells, pt.size = 2)
#tsne data
svg(filename = "umap_plot.svg",height=5, width = 6.15, pointsize = 12)
UMAPPlot(object = wild_type_cells, group.by = "condition", pt.size = 1.6)
dev.off()
# calculate size normalization





normexp <- sweep(unnormexp, 2, sizef, "/")
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#add to monocle object
HSMM@assayData$exprs_sfnorm <- normexp
library(monocle)
#run monocle size factor and dispersion functios
CMdata <- estimateSizeFactors(CMdata)
CMdata <- estimateDispersions(CMdata)
CMdata <- detectGenes(CMdata, min_expr = 0.1)
#run differential expression gene test
diff_test_res <- differentialGeneTest(CMdata, fullModelFormulaStr = "~timepoint")
#
ordering_genes <- row.names (subset(diff_test_res, qval < 0.01))
CMdata <- setOrderingFilter(CMdata, ordering_genes)
plot_ordering_genes(CMdata)
#reduce dimension





plot_cell_trajectory(CMdata, color_by = "matt", size=2)
## diff exp for P7
diff_test_res_P7 <- differentialGeneTest(CMdata[, pData(CMdata)$condition %in% c("
P07␣RFP-","P07␣RFP+")], fullModelFormulaStr = "~matt")
sig_genes <- subset(diff_test_res_P7, qval < 0.1)
## Select
sig_genes <- sig_genes[,c("gene_short_name", "pval", "qval")]
#calculate fold change
CMdata_p7 <- CMdata[, pData(CMdata)$condition %in% c("P07␣RFP-","P07␣RFP+")]
# get average expression for each group
P00wt <- as.matrix(rowMeans(as.matrix(CMdata_new[, pData(CMdata_new)$condition %in
% c("P00␣RFP-")]@assayData$exprs_sfnorm)))
### plotting genexp vs pseudotime
plotgene_exp <- function(gene) { #gene is a string eg "Myh6"
#select pseudotime vecetor
pst <- as.matrix(HSMM_wtsub2@phenoData@data$Pseudotime)
#convert to normalized expression to log2
expv <- log2(as.matrix(HSMM_wtsub2@assayData$exprs_sfnorm[gene,])+1)
#merge pseudotime and expressoin
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p_exp <- as.data.frame(cbind(as.numeric(pst), as.numeric(expv)))
colnames(p_exp) <- c("pst","expv") #set column names
#plot using ggplot2
library(ggplot2)







theme_bw(base_size = 20) +
theme(panel.grid.major = element_blank(),
panel.grid.minor = element_blank(),
panel.background = element_rect(colour = "black", size=4),
axis.text.x = element_text(colour = "black"),
axis.text.y = element_text(colour = "black")
)
}
goi <- "Yap1" #gene of interest
HSMM_p7 <- HSMM[,HSMM@phenoData@data$timepoint == "P07"] #subset to p7
expd <- HSMM_p7@assayData$exprs_sfnorm[goi,] #select the size factor normalized
data for the gene of interest
rfpstat <- HSMM_p7@phenoData@data$rfp #
timepointstat <- HSMM_p7@phenoData@data$timepoint
df2 <- as.data.frame(cbind(as.numeric(expd),rfpstat,timepointstat))
Yap1-plot <- ggplot(data = df2, aes(x=timepointstat,y=expd,fill=rfpstat))+
geom_bar(stat = "summary", fun.y="mean", position = position_dodge(1.1), colour
= "black") +
stat_summary(fun.data = mean_se,geom="errorbar",width=0.15, position = position_
dodge(1.1)) +
theme_classic(base_size = 20) +
scale_y_continuous(expand=c(0,0))
yexp_rfp <- expd[rfpstat == "RFP+"]











bFGF basic fibroblast growth factor
CASAAV CRISPR/Cas9-AAV-based somatic mutagenesis
ChIP chromatin immunoprecipitation
CM cardiomyocyte
cmKO conditional mosaic knock out
CTD calcium transient duration
DAPI 4’,6-diamidino-2-phenylindole





EHT engineered heart tissue
ERR estrogen related receptor
ESC embryonic stem cell
FACS fluorescent activated cell sorting
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fRMA frozen robust multi-array
GC genome copy
GEO gene expression omnibus
GFP green fluorescent protein
GO gene ontology
GRN gene regulatory network
HCN4 hyperpolarization activated cyclic nucleotide gated potassium channel 4
HIF1a hypoxia-inducible factor 1a
IPA ingenuity pathway analysis
iPSC induced pluripotent stem cell
KD-D Kolmogorov-Smirnov distance
KEGG Kyoto Encyclopedia of Genes and Genomes
KHK ketohexokinase
lncRNA long noncoding RNAs
LP-FACS large particle fluorscent activated cell sorting
MACS model-based analysis of ChIP-seq
mcSCRB-seq molecular crowding single cell RNA-barcoding and sequencing
miRNA microRNA
NCBI National Center for Biotechnology Information (NCBI)
NES normalized enrichment score
OCR oxygen consumption rate
PAR-CLIP photoactivatable ribonucleoside-enhanced crosslinking immunoprecipitation
PBS phosphate-buffered saline
PCA principal component analysis
PCR polymerase chain reaction
PDMS polydimethylsiloxane
PGC1a PPAR gamma coactivator 1 alpha
PPAR Peroxisome proliferator activation receptor
PSC pluripotent stem cell
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PSC-CM pluripotent stem cell-derived cardiomyocyte
qPCR quantitative polymerase chain reaction
RFP red fluorescent protein
RNA ribonucleic acid
ROS reactive oxygen species
RPM Revolutions Per Minute
SERCA sarco/endoplasmi reticulum calcium ATPase
SF3B2 splicing factor 3 B2
siRNA small interferring ribonucleic acid
snRNP small nuclear ribonucleoprotein
SRA sequence read archive
SRF serum response factor
T3 tri-iodothryonine
TAC transverse aortic constriction
TEM transmisison electron microscopy
t-SNE t-distributed stochastic neighbor embedding
UMAP uniform manifold approximation and projection for dimension reduction
UMI unique molecular identifier
VEGF vascular endothelial growth factor
WGA wheat germ agglutinin
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